Communication system with enhanced partial power source and method of manufacturing same

Information

  • Patent Grant
  • 10517507
  • Patent Number
    10,517,507
  • Date Filed
    Wednesday, June 18, 2014
    9 years ago
  • Date Issued
    Tuesday, December 31, 2019
    4 years ago
Abstract
The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can also measure the conditions of the environment surrounding the system.
Description
FIELD

The present invention is related to communication systems for detection of an event. More specifically, the present disclosure includes a system that includes a device with various power sources and communication schemes.


INTRODUCTION

Ingestible devices that include electronic circuitry have been proposed for use in a variety of different medical applications, including both diagnostic and therapeutic applications. These devices typically require an internal power supply for operation. Examples of such ingestible devices are ingestible electronic capsules which collect data as they pass through the body, and transmit the data to an external receiver system. An example of this type of electronic capsule is an in-vivo video camera. The swallowable capsule includes a camera system and an optical system for imaging an area of interest onto the camera system. The transmitter transmits the video output of the camera system and the reception system receives the transmitted video output. Other examples include an ingestible imaging device, which has an internal and self-contained power source, which obtains images from within body lumens or cavities. The electronic circuit components of the device are enclosed by an inert indigestible housing (e.g. glass housing) that passes through the body internally. Other examples include an ingestible data recorder capsule medical device. The electronic circuits of the disclosed device (e.g. sensor, recorder, battery etc.) are housed in a capsule made of inert materials.


In other examples, fragile radio frequency identification (RFID) tags are used in drug ingestion monitoring applications. In order for the RFID tags to be operational, each requires an internal power supply. The RFID tags are antenna structures that are configured to transmit a radio-frequency signal through the body.


The problem these existing devices pose is that the power source is internal to device and such power sources are costly to produce and potentially harmful to the surrounding environment if the power source leaks or is damaged. Additionally, having antennas extending from the device is a concern as related to the antennas getting damaged or causing a problem when the device is used in-vivo. Therefore, what is needed is suitable system with circuitry that eliminates the need for an internal power source and antennas.


SUMMARY

The present disclosure includes a system for producing a unique signature that indicates the occurrence of an event. The system includes circuitry and components that can be placed within certain environments that include a conducting fluid. One example of such an environment is inside a container that houses the conducting fluid, such as a sealed bag with a solution, which includes an IV bag. Another example is within the body of a living organism, such as an animal or a human. The systems are ingestible and/or digestible or partially digestible. The system includes dissimilar materials positioned on the framework such that when a conducting fluid comes into contact with the dissimilar materials, a voltage potential difference is created. The voltage potential difference, and hence the voltage, is used to power up control logic that is positioned within the framework. Ions or current flows from the first dissimilar material to the second dissimilar material via the control logic and then through the conducting fluid to complete a circuit. The control logic controls the conductance between the two dissimilar materials and, hence, controls or modulates the conductance.


As the ingestible circuitry is made up of ingestible, and even digestible, components, the ingestible circuitry results in little, if any, unwanted side effects, even when employed in chronic situations. Examples of the range of components that may be included are: logic and/or memory elements; effectors; a signal transmission element; and a passive element, such as a resistor or inductor. The one or more components on the surface of the support may be laid out in any convenient configuration. Where two or more components are present on the surface of the solid support, interconnects may be provided. All of the components and the support of the ingestible circuitry are ingestible, and in certain instances digestible or partially digestible. Furthermore, the circuitry is manufactured according to a process to enhance adhesion of the materials.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 shows a pharmaceutical product with an event indicator system according to the teaching of the present invention, wherein the product and the event indicator system combination are within the body.



FIG. 2A shows the pharmaceutical product of FIG. 1 with the event indicator system on the exterior of the pharmaceutical product.



FIG. 2B shows the pharmaceutical product of FIG. 1 with the event indicator system positioned inside the pharmaceutical product.



FIG. 3 is a block diagram representation of one aspect of the event indicator system with dissimilar metals positioned on opposite ends.



FIG. 4 is a block diagram representation of another aspect of the event indicator system with dissimilar metals positioned on the same end and separated by a non-conducting material.



FIG. 5 shows ionic transfer or the current path through a conducting fluid when the event indicator system of FIG. 3 is in contact with conducting liquid and in an active state.



FIG. 5A shows an exploded view of the surface of dissimilar materials of FIG. 5.



FIG. 5B shows the event indicator system of FIG. 5 with a pH sensor unit.



FIG. 5C shows the event indicator system in accordance with another aspect of the present invention.



FIG. 6 is a block diagram illustration of one aspect of the control device used in the system of FIGS. 3 and 4.



FIG. 7 shows a cross sectional side view of the event indicator system in accordance with the present invention.



FIG. 8 is an exploded view of two components of the event indicator system of FIG. 7 in accordance with the present invention.



FIG. 9 is an assembly process of a portion of the event indicator system of FIG. 7 in accordance with the present invention.



FIG. 10 shows a wafer with multiple event indicator systems in accordance with the present invention.



FIG. 11 shows a non-conducting membrane sheet with holes for receiving a device forming part of the event indicator system of FIG. 7 in accordance with the present invention.





DETAILED DESCRIPTION

The present disclosure includes multiple aspects for indicating the occurrence of an event. As described in more detail below, a system of the present invention is used with a conducting fluid to indicate the event marked by contact between the conducting fluid and the system. For example, the system of the present disclosure may be used with pharmaceutical product and the event that is indicated is when the product is taken or ingested. The term “ingested” or “ingest” or “ingesting” is understood to mean any introduction of the system internal to the body. For example, ingesting includes simply placing the system in the mouth all the way to the descending colon. Thus, the term ingesting refers to any instant in time when the system is introduced to an environment that contains a conducting fluid. Another example would be a situation when a non-conducting fluid is mixed with a conducting fluid. In such a situation the system would be present in the non-conduction fluid and when the two fluids are mixed, the system comes into contact with the conducting fluid and the system is activated. Yet another example would be the situation when the presence of certain conducting fluids needed to be detected. In such instances, the presence of the system, which would be activated, within the conducting fluid could be detected and, hence, the presence of the respective fluid would be detected.


Referring again to the instance where the system is used with the product that is ingested by the living organism, when the product that includes the system is taken or ingested, the device comes into contact with the conducting liquid of the body. When the system of the present invention comes into contact with the body fluid, a voltage potential is created and the system is activated. A portion of the power source is provided by the device, while another portion of the power source is provided by the conducting fluid, which is discussed in detail below.


Referring now to FIG. 1, an ingestible product 14 that includes a system of the present invention is shown inside the body. The product 14 is configured as an orally ingestible pharmaceutical formulation in the form of a pill or capsule. Upon ingestion, the pill moves to the stomach. Upon reaching the stomach, the product 14 is in contact with stomach fluid 18 and undergoes a chemical reaction with the various materials in the stomach fluid 18, such as hydrochloric acid and other digestive agents. The system of the present invention is discussed in reference to a pharmaceutical environment. However, the scope of the present invention is not limited thereby. The present invention can be used in any environment where a conducting fluid is present or becomes present through mixing of two or more components that result in a conducting liquid.


Referring now to FIG. 2A, a pharmaceutical product 10, similar to the product 14 of FIG. 1, is shown with a system 12, such as an ingestible event marker or an ionic emission module. The scope of the present invention is not limited by the shape or type of the product 10. For example, it will be clear to one skilled in the art that the product 10 can be a capsule, a time-release oral dosage, a tablet, a gel cap, a sub-lingual tablet, or any oral dosage product that can be combined with the system 12. In the referenced aspect, the product 10 has the system 12 secured to the exterior using known methods of securing micro-devices to the exterior of pharmaceutical products. Example of methods for securing the micro-device to the product is disclosed in U.S. Provisional Application No. 61/142,849 filed on Jan. 1, 2009 and entitled “HIGH-THROUGHPUT PRODUCTION OF INGESTIBLE EVENT MARKERS” as well as U.S. Provisional Application No. 61/177,611 filed on May 12, 2009 and entitled “INGESTIBLE EVENT MARKERS COMPRISING AN IDENTIFIER AND AN INGESTIBLE COMPONENT”, the entire disclosure of each is incorporated herein by reference. Once ingested, the system 12 comes into contact with body liquids and the system 12 is activated. The system 12 uses the voltage potential difference to power up and thereafter modulates conductance to create a unique and identifiable current signature. Upon activation, the system 12 controls the conductance and, hence, current flow to produce the current signature.


There are various reasons for delaying the activation of the system 12. In order to delay the activation of the system 12, the system 12 may be coated with a shielding material or protective layer. The layer is dissolved over a period of time, thereby allowing the system 12 to be activated when the product 10 has reached a target location.


Referring now to FIG. 2B, a pharmaceutical product 20, similar to the product 14 of FIG. 1, is shown with a system 22, such as an ingestible event marker or an identifiable emission module. The scope of the present invention is not limited by the environment to which the system 22 is introduced. For example, the system 22 can be enclosed in a capsule that is taken in addition to/independently from the pharmaceutical product. The capsule may be simply a carrier for the system 22 and may not contain any product. Furthermore, the scope of the present invention is not limited by the shape or type of product 20. For example, it will be clear to one skilled in the art that the product 20 can be a capsule, a time-release oral dosage, a tablet, a gel capsule, a sub-lingual tablet, or any oral dosage product. In the referenced aspect, the product 20 has the system 22 positioned inside or secured to the interior of the product 20. In one aspect, the system 22 is secured to the interior wall of the product 20. When the system 22 is positioned inside a gel capsule, then the content of the gel capsule is a non-conducting gel-liquid. On the other hand, if the content of the gel capsule is a conducting gel-liquid, then in an alternative aspect, the system 22 is coated with a protective cover to prevent unwanted activation by the gel capsule content. If the content of the capsule is a dry powder or microspheres, then the system 22 is positioned or placed within the capsule. If the product 20 is a tablet or hard pill, then the system 22 is held in place inside the tablet. Once ingested, the product 20 containing the system 22 is dissolved. The system 22 comes into contact with body liquids and the system 22 is activated. Depending on the product 20, the system 22 may be positioned in either a near-central or near-perimeter position depending on the desired activation delay between the time of initial ingestion and activation of the system 22. For example, a central position for the system 22 means that it will take longer for the system 22 to be in contact with the conducting liquid and, hence, it will take longer for the system 22 to be activated. Therefore, it will take longer for the occurrence of the event to be detected.


Referring now to FIG. 3, in one aspect, the systems 12 and 22 of FIGS. 2A and 2B, respectively, are shown in more detail as system 30. The system 30 can be used in association with any pharmaceutical product, as mentioned above, to determine when a patient takes the pharmaceutical product. As indicated above, the scope of the present invention is not limited by the environment and the product that is used with the system 30. For example, the system 30 may be placed within a capsule and the capsule is placed within the conducting liquid. The capsule would then dissolve over a period of time and release the system 30 into the conducting liquid. Thus, in one aspect, the capsule would contain the system 30 and no product. Such a capsule may then be used in any environment where a conducting liquid is present and with any product. For example, the capsule may be dropped into a container filled with jet fuel, salt water, tomato sauce, motor oil, or any similar product. Additionally, the capsule containing the system 30 may be ingested at the same time that any pharmaceutical product is ingested in order to record the occurrence of the event, such as when the product was taken.


In the specific example of the system 30 combined with the pharmaceutical product, as the product or pill is ingested, the system 30 is activated. The system 30 controls conductance to produce a unique current signature that is detected, thereby signifying that the pharmaceutical product has been taken. The system 30 includes a framework 32. The framework 32 is a chassis for the system 30 and multiple components are attached to, deposited upon, or secured to the framework 32. In this aspect of the system 30, a digestible material 34 is physically associated with the framework 32. The material 34 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework all of which may be referred to herein as “deposit” with respect to the framework 32. The material 34 is deposited on one side of the framework 32. The materials of interest that can be used as material 34 include, but are not limited to: Cu or CuI. The material 34 is deposited by physical vapor deposition, electrodeposition, or plasma deposition, among other protocols. The material 34 may be from about 0.05 to about 500 μm thick, such as from about 5 to about 100 μm thick. The shape is controlled by shadow mask deposition, or photolithography and etching. Additionally, even though only one region is shown for depositing the material, each system 30 may contain two or more electrically unique regions where the material 34 may be deposited, as desired. The various methods for depositing the materials onto the framework 32 are discussed in greater detail with respect to FIGS. 7-9 below.


At a different side, which is the opposite side as shown in FIG. 3, another digestible material 36 is deposited, such that materials 34 and 36 are dissimilar. Although not shown, the different side selected may be the side next to the side selected for the material 34. The scope of the present invention is not limited by the side selected and the term “different side” can mean any of the multiple sides that are different from the first selected side. Furthermore, even though the shape of the system is shown as a square, the shape maybe any geometrically suitable shape. Material 34 and 36 are selected such that they produce a voltage potential difference when the system 30 is in contact with conducting liquid, such as body fluids. The materials of interest for material 36 include, but are not limited to: Mg, Zn, or other electronegative metals. As indicated above with respect to the material 34, the material 36 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework. Also, an adhesion layer may be necessary to help the material 36 (as well as material 34 when needed) to adhere to the framework 32. Typical adhesion layers for the material 36 are Ti, TiW, Cr or similar material. Anode material and the adhesion layer may be deposited by physical vapor deposition, electrodeposition or plasma deposition. The material 36 may be from about 0.05 to about 500 μm thick, such as from about 5 to about 100 μm thick. However, the scope of the present invention is not limited by the thickness of any of the materials nor by the type of process used to deposit or secure the materials to the framework 32.


According to the disclosure set forth, the materials 34 and 36 can be any pair of materials with different electrochemical potentials. Additionally, in the aspects wherein the system 30 is used in-vivo, the materials 34 and 36 may be vitamins that can be absorbed. More specifically, the materials 34 and 36 can be made of any two materials appropriate for the environment in which the system 30 will be operating. For example, when used with an ingestible product, the materials 34 and 36 are any pair of materials with different electrochemical potentials that are ingestible. An illustrative example includes the instance when the system 30 is in contact with an ionic solution, such as stomach acids. Suitable materials are not restricted to metals, and in certain aspects the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as CuCl or CuI). With respect to the active electrode materials, any pairing of substances—metals, salts, or intercalation compounds—with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.


Materials and pairings of interest include, but are not limited to, those reported in Table 1 below. In one aspect, one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage potential created between the materials as they come into contact with a conducting liquid. Non-metals that may be used as doping agents in certain aspects include, but are not limited to: sulfur, iodine and the like. In another aspect, the materials are copper iodine (CuI) as the anode and magnesium (Mg) as the cathode. Aspects of the present invention use electrode materials that are not harmful to the human body.












TABLE 1







Anode
Cathode


















Metals
Magnesium, Zinc




Sodium, Lithium



Iron


Salts

Copper salts: iodide, chloride, bromide,




sulfate, formate, (other anions possible)




Fe3+ salts: e.g. orthophosphate,




pyrophosphate, (other anions possible)




Oxygen or Hydrogen ion (H+) on




platinum, gold or other catalytic




surfaces


Intercalation
Graphite with Li,
Vanadium oxide


compounds
K, Ca, Na, Mg
Manganese oxide









Thus, when the system 30 is in contact with the conducting liquid, a current path, an example is shown in FIG. 5, is formed through the conducting liquid between material 34 and 36. A control device 38 is secured to the framework 32 and electrically coupled to the materials 34 and 36. The control device 38 includes electronic circuitry, for example control logic that is capable of controlling and altering the conductance between the materials 34 and 36.


The voltage potential created between the materials 34 and 36 provides the power for operating the system as well as produces the current flow through the conducting fluid and the system. In one aspect, the system operates in direct current mode. In an alternative aspect, the system controls the direction of the current so that the direction of current is reversed in a cyclic manner, similar to alternating current. As the system reaches the conducting fluid or the electrolyte, where the fluid or electrolyte component is provided by a physiological fluid, e.g., stomach acid, the path for current flow between the materials 34 and 36 is completed external to the system 30; the current path through the system 30 is controlled by the control device 38. Completion of the current path allows for the current to flow and in turn a receiver, not shown, can detect the presence of the current and recognize that the system 30 has been activate and the desired event is occurring or has occurred.


In one aspect, the two materials 34 and 36 are similar in function to the two electrodes needed for a direct current power source, such as a battery. The conducting liquid acts as the electrolyte needed to complete the power source. The completed power source described is defined by the electrochemical reaction between the materials 34 and 36 of the system 30 and enabled by the fluids of the body. The completed power source may be viewed as a power source that exploits electrochemical conduction in an ionic or a conducting solution such as gastric fluid, blood, or other bodily fluids and some tissues. Additionally, the environment may be something other than a body and the liquid may be any conducting liquid. For example, the conducting fluid may be salt water or a metallic based paint.


In certain aspects, these two materials are shielded from the surrounding environment by an additional layer of material. Accordingly, when the shield is dissolved and the two dissimilar materials are exposed to the target site, a voltage potential is generated.


In certain aspects, the complete power source or supply is one that is made up of active electrode materials, electrolytes, and inactive materials, such as current collectors, packaging, etc. The active materials are any pair of materials with different electrochemical potentials. Suitable materials are not restricted to metals, and in certain aspects the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as CuI). With respect to the active electrode materials, any pairing of substances—metals, salts, or intercalation compounds—with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.


A variety of different materials may be employed as the materials that form the electrodes. In certain aspects, electrode materials are chosen to provide for a voltage upon contact with the target physiological site, e.g., the stomach, sufficient to drive the system of the identifier. In certain aspects, the voltage provided by the electrode materials upon contact of the metals of the power source with the target physiological site is 0.001 V or higher, including 0.01 V or higher, such as 0.1 V or higher, e.g., 0.3 V or higher, including 0.5 volts or higher, and including 1.0 volts or higher, where in certain aspects, the voltage ranges from about 0.001 to about 10 volts, such as from about 0.01 to about 10 V.


Referring again to FIG. 3, the materials 34 and 36 provide the voltage potential to activate the control device 38. Once the control device 38 is activated or powered up, the control device 38 can alter conductance between the materials 34 and 36 in a unique manner. By altering the conductance between materials 34 and 36, the control device 38 is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system 30. This produces a unique current signature that can be detected and measured by a receiver (not shown), which can be positioned internal or external to the body. In addition to controlling the magnitude of the current path between the materials, non-conducting materials, membrane, or “skirt” are used to increase the “length” of the current path and, hence, act to boost the conductance path, as disclosed in the U.S. patent application Ser. No. 12/238,345 entitled, “In-Body Device with Virtual Dipole Signal Amplification” filed Sep. 25, 2008, the entire content of which is incorporated herein by reference. Alternatively, throughout the disclosure herein, the terms “non-conducting material”, “membrane”, and “skirt” are used interchangeably with the term “current path extender” without impacting the scope or the present aspects and the claims herein. The skirt, shown in portion at 35 and 37, respectively, may be associated with, e.g., secured to, the framework 32. Various shapes and configurations for the skirt are contemplated as within the scope of the present invention. For example, the system 30 may be surrounded entirely or partially by the skirt and the skirt maybe positioned along a central axis of the system 30 or off-center relative to a central axis. Thus, the scope of the present invention as claimed herein is not limited by the shape or size of the skirt. Furthermore, in other aspects, the materials 34 and 36 may be separated by one skirt that is positioned in any defined region between the materials 34 and 36.


Referring now to FIG. 4, in another aspect, the systems 12 and 22 of FIGS. 2A and 2B, respectively, are shown in more detail as system 40. The system 40 includes a framework 42. The framework 42 is similar to the framework 32 of FIG. 3. In this aspect of the system 40, a digestible or dissolvable material 44 is deposited on a portion of one side of the framework 42. At a different portion of the same side of the framework 42, another digestible material 46 is deposited, such that materials 44 and 46 are dissimilar. More specifically, material 44 and 46 are selected such that they form a voltage potential difference when in contact with a conducting liquid, such as body fluids. Thus, when the system 40 is in contact with and/or partially in contact with the conducting liquid, then a current path, an example is shown in FIG. 5, is formed through the conducting liquid between material 44 and 46. A control device 48 is secured to the framework 42 and electrically coupled to the materials 44 and 46. The control device 48 includes electronic circuitry that is capable of controlling part of the conductance path between the materials 44 and 46. The materials 44 and 46 are separated by a non-conducting skirt 49. Various examples of the skirt 49 are disclosed in U.S. Provisional Application No. 61/173,511 filed on Apr. 28, 2009 and entitled “HIGHLY RELIABLE INGESTIBLE EVENT MARKERS AND METHODS OF USING SAME” and U.S. Provisional Application No. 61/173,564 filed on Apr. 28, 2009 and entitled “INGESTIBLE EVENT MARKERS HAVING SIGNAL AMPLIFIERS THAT COMPRISE AN ACTIVE AGENT”; as well as U.S. application Ser. No. 12/238,345 filed Sep. 25, 2008 and entitled “IN-BODY DEVICE WITH VIRTUAL DIPOLE SIGNAL AMPLIFICATION”; the entire disclosure of each is incorporated herein by reference.


Once the control device 48 is activated or powered up, the control device 48 can alter conductance between the materials 44 and 46. Thus, the control device 48 is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system 40. As indicated above with respect to system 30, a unique current signature that is associated with the system 40 can be detected by a receiver (not shown) to mark the activation of the system 40. In order to increase the “length” of the current path the size of the skirt 49 is altered. The longer the current path, the easier it may be for the receiver to detect the current.


Referring now to FIG. 5, the system 30 of FIG. 3 is shown in an activated state and in contact with conducting liquid. The system 30 is grounded through ground contact 52. For example, when the system 30 is in contact with a conducting fluid, the conducting fluid provides the ground. The system 30 also includes a sensor module 74, which is described in greater detail with respect to FIG. 6. Ion or current paths 50 extend between material 34 to material 36 and flow through the conducting fluid in contact with the system 30. The voltage potential created between the material 34 and 36 is created through chemical reactions between materials 34/36 and the conducting fluid.


If the conditions of the environment change to become favorable to communication, as determined by the measurements of the environment, then the unit 75 sends a signal to the control device 38 to alter the conductance between the materials 34 and 36 to allow for communication using the current signature of the system 30. Thus, if the system 30 has been deactivated and the impedance of the environment is suitable for communication, then the system 30 can be activated again.


Referring now to FIG. 5A, this shows an exploded view of the surface of the material 34. In one aspect, the surface of the material 34 is not planar, but rather an irregular surface. The irregular surface increases the surface area of the material and, hence, the area that comes in contact with the conducting fluid. In one aspect, at the surface of the material 34, there is an electrochemical reaction between the material 34 and the surrounding conducting fluid such that mass is exchanged with the conducting fluid. The term “mass” as used here includes any ionic or non-ionic species that may be added or removed from the conductive fluid as part of the electrochemical reactions occurring on material 34. One example includes the instant where the material is CuCl and when in contact with the conducting fluid, CuCl is converted to Cu metal (solid) and Cl— is released into the solution. The flow of positive ions into the conducting fluid is depicted by the current path 50. Negative ions flow in the opposite direction. In a similar manner, there is an electrochemical reaction involving the material 36 that results in ions released or removed from the conducting fluid. In this example, the release of negative ions at the material 34 and release of positive ions by the material 36 are related to each other through the current flow that is controlled by the control device 38. The rate of reaction and hence the ionic emission rate or current, is controlled by the control device 38. The control device 38 can increase or decrease the rate of ion flow by altering its internal conductance, which alters the impedance, and therefore the current flow and reaction rates at the materials 34 and 36. Through controlling the reaction rates, the system 30 can encode information in the ionic flow. Thus, the system 30 encodes information using ionic emission or flow.


The control device 38 can vary the duration of ionic flow or current while keeping the current or ionic flow magnitude near constant, similar to when the frequency is modulated and the amplitude is constant. Also, the control device 38 can vary the level of the ionic flow rate or the magnitude of the current flow while keeping the duration near constant. Thus, using various combinations of changes in duration and altering the rate or magnitude, the control device 38 encodes information in the current or the ionic flow. For example, the control device 38 may use, but is not limited to any of the following techniques, including Binary Phase-Shift Keying (PSK), Frequency modulation, Amplitude modulation, on-off keying, and PSK with on-off keying.


As indicated above, the various aspects disclosed herein, such as systems 30 and 40 of FIGS. 3 and 4, respectively, include electronic components as part of the control device 38 or the control device 48. Components that may be present include but are not limited to: logic and/or memory elements, an integrated circuit, an inductor, a resistor, and sensors for measuring various parameters. Each component may be secured to the framework and/or to another component. The components on the surface of the support may be laid out in any convenient configuration. Where two or more components are present on the surface of the solid support, interconnects may be provided.


As indicated above, the system, such as control devices 30 and 40, control the conductance between the dissimilar materials and, hence, the rate of ionic flow or current. Through altering the conductance in a specific manner the system is capable of encoding information in the ionic flow and the current signature. The ionic flow or the current signature is used to uniquely identify the specific system. Additionally, the systems 30 and 40 are capable of producing various different unique patterns or signatures and, thus, provide additional information. For example, a second current signature based on a second conductance alteration pattern may be used to provide additional information, which information may be related to the physical environment. To further illustrate, a first current signature may be a very low current state that maintains an oscillator on the chip and a second current signature may be a current state at least a factor of ten higher than the current state associated with the first current signature.


Referring now to FIG. 6, a block diagram representation of the control device 38 is shown. The device 30 includes a control module 62, a counter or clock 64, and a memory 66. Additionally, the control device 38 is shown to include a sensor module 72 as well as the sensor module 74, which was referenced in FIG. 5. The control module 62 has an input 68 electrically coupled to the material 34 and an output 70 electrically coupled to the material 36. The control module 62, the clock 64, the memory 66, and the sensor modules 72/74 also have power inputs (some not shown). The power for each of these components is supplied by the voltage potential produced by the chemical reaction between materials 34 and 36 and the conducting fluid, when the system 30 is in contact with the conducting fluid. The control module 62 controls the conductance through logic that alters the overall impedance of the system 30. The control module 62 is electrically coupled to the clock 64. The clock 64 provides a clock cycle to the control module 62. Based upon the programmed characteristics of the control module 62, when a set number of clock cycles have passed, the control module 62 alters the conductance characteristics between materials 34 and 36. This cycle is repeated and thereby the control device 38 produces a unique current signature characteristic. The control module 62 is also electrically coupled to the memory 66. Both the clock 64 and the memory 66 are powered by the voltage potential created between the materials 34 and 36.


The control module 62 is also electrically coupled to and in communication with the sensor modules 72 and 74. In the aspect shown, the sensor module 72 is part of the control device 38 and the sensor module 74 is a separate component. In alternative aspects, either one of the sensor modules 72 and 74 can be used without the other and the scope of the present invention is not limited by the structural or functional location of the sensor modules 72 or 74. Additionally, any component of the system 30 may be functionally or structurally moved, combined, or repositioned without limiting the scope of the present invention as claimed. Thus, it is possible to have one single structure, for example a processor, which is designed to perform the functions of all of the following modules: the control module 62, the clock 64, the memory 66, and the sensor module 72 or 74. On the other hand, it is also within the scope of the present invention to have each of these functional components located in independent structures that are linked electrically and able to communicate.


Referring again to FIG. 6, the sensor modules 72 or 74 can include any of the following sensors: temperature, pressure, pH level, and conductivity. In one aspect, the sensor modules 72 or 74 gather information from the environment and communicate the analog information to the control module 62. The control module then converts the analog information to digital information and the digital information is encoded in the current flow or the rate of the transfer of mass that produces the ionic flow. In another aspect, the sensor modules 72 or 74 gather information from the environment and convert the analog information to digital information and then communicate the digital information to control module 62. In the aspect shown in FIG. 5, the sensor modules 74 is shown as being electrically coupled to the material 34 and 36 as well as the control device 38. In another aspect, as shown in FIG. 6, the sensor module 74 is electrically coupled to the control device 38 at connection 78. The connection 78 acts as both a source for power supply to the sensor module 74 and a communication channel between the sensor module 74 and the control device 38.


Referring now to FIG. 5B, the system 30 includes a pH sensor module 76 connected to a material 39, which is selected in accordance with the specific type of sensing function being performed. The pH sensor module 76 is also connected to the control device 38. The material 39 is electrically isolated from the material 34 by a non-conductive barrier 55. In one aspect, the material 39 is platinum. In operation, the pH sensor module 76 uses the voltage potential difference between the materials 34/36. The pH sensor module 76 measures the voltage potential difference between the material 34 and the material 39 and records that value for later comparison. The pH sensor module 76 also measures the voltage potential difference between the material 39 and the material 36 and records that value for later comparison. The pH sensor module 76 calculates the pH level of the surrounding environment using the voltage potential values. The pH sensor module 76 provides that information to the control device 38. The control device 38 varies the rate of the transfer of mass that produces the ionic transfer and the current flow to encode the information relevant to the pH level in the ionic transfer, which can be detected by a receiver (not shown). Thus, the system 30 can determine and provide the information related to the pH level to a source external to the environment.


As indicated above, the control device 38 can be programmed in advance to output a pre-defined current signature. In another aspect, the system can include a receiver system that can receive programming information when the system is activated. In another aspect, not shown, the switch 64 and the memory 66 can be combined into one device.


In addition to the above components, the system 30 may also include one or other electronic components. Electrical components of interest include, but are not limited to: additional logic and/or memory elements, e.g., in the form of an integrated circuit; a power regulation device, e.g., battery, fuel cell or capacitor; a sensor, a stimulator, etc.; a signal transmission element, e.g., in the form of an antenna, electrode, coil, etc.; a passive element, e.g., an inductor, resistor, etc.


Referring now to FIG. 5C, the system 30 is shown with the skirt portions 35 and 37 secured to the framework 32, as discussed in detail below. In accordance with one aspect of the present invention, the material 34 and the material 36 extend beyond the framework 32 onto the skirt portions 35 and 37. In another example in accordance with the present invention, the materials 34 and 36 can extend to the edge of the skirt portions 35 and 37. The increase in the area of the materials 34 and 36 results in an increase in the power supplied.


Referring now to FIG. 7, a cross-sectional view is shown of the system 30 with a first material region 34a and a second material region 36a on the framework 32. The first material region 34a includes an adhering material 86. The adhering material 86 can be any material selected to adhere and hold onto a first material region 88, which material region 88 is made of CuCl in accordance with one aspect of the present invention as discussed above with respect to the first material 34. The second material region 36a includes a transition metal 96 that is made of any transition metal, for example titanium in accordance with one aspect of the present invention. The second material region 36a also includes a second material region 98, which is made of magnesium (Mg) in accordance with one aspect of the present invention as discussed above with respect to the second material 36.


Referring now to FIG. 8, an exploded view of the material 86 and the material region 88 is shown. The material 86 is made of a non-reactive and conducting material, for example gold. To enhance the adhesion properties of the material 86 to the material region 88, the material 86 has an unfinished or rough surface. The material 86 is deposited onto the framework 32. Additionally, according to one aspect of the present invention, the material 86 defines a plurality of holes 87 spaced a distance DD from the edge of the framework 32 corresponding to the edge of the material 86. The distance DD is the minimum distance that is needed to separate the holes 87 from the edge of the material 86 and allow all the of the holes 87 to fall within a boundary 89 so that the edge of the material region 88 is not positioned over any hole; this design enhances the adhesion property and characteristics of the material 86 to the material region 88.


Referring now to FIG. 9, a process of securing the metal 96 to the framework 32 is shown. Initially the metal 96 is deposited onto the framework 32. Then the metal 86 with the framework 32 is heated. Then the surface of the metal 96 is cleaned using, for example, an ion gun cleaner. Then the magnesium is deposited onto the cleaned surface of the metal 86 to form the material region 98.


In accordance with another aspect of the present invention, a plurality of frameworks 32, as shown in FIG. 1, are built on a wafer 100, as shown in the top view illustration of FIG. 10. The wafer 100 can include any number of frameworks 32. Once the wafer 100 is complete, then each complete framework 32 is cut from the wafer 100 and inserted or press fitted or placed into an opening 112 of FIG. 11 of a sheet 110 to produce the system 12, 22, 30, or 40 as shown and discussed about in accordance with the various aspects of the present invention. The opening 112 is matingly cut to the shape of the framework 32. The sheet 110 is then passed through a punch press (not shown) that punches out each of systems 12, 22, 30, or 40 as noted.


In certain aspects, the ingestible circuitry includes a coating layer. In accordance with one aspect of the present invention, the protective coating may be applied to the wafer 100 using a spinning process prior to removal of the framework 32 from the wafer 100 of FIG. 10. In accordance with another aspect of the present invention, the protective coating may be applied to the system, for example the system 30, after being punched out or cut out from the sheet 110 of FIG. 11. The purpose of this coating layer can vary, e.g., to protect the circuitry, the chip and/or the battery, or any components during processing, during storage, or even during ingestion. In such instances, a coating on top of the circuitry may be included. Also of interest are coatings that are designed to protect the ingestible circuitry during storage, but dissolve immediately during use. For example, coatings that dissolve upon contact with an aqueous fluid, e.g. stomach fluid, or the conducting fluid as referenced above. Also of interest are protective processing coatings that are employed to allow the use of processing steps that would otherwise damage certain components of the device. For example, in aspects where a chip with dissimilar material deposited on the top and bottom is produced, the product needs to be diced. However, the dicing process can scratch off the dissimilar material, and also there might be liquid involved which would cause the dissimilar materials to discharge or dissolve. In such instances, a protective coating on the materials prevents mechanical or liquid contact with the component during processing can be employed.


Another purpose of the dissolvable coatings may be to delay activation of the device. For example, the coating that sits on the dissimilar material and takes a certain period of time, e.g., five minutes, to dissolve upon contact with stomach fluid may be employed. The coating can also be an environmentally sensitive coating, e.g., a temperature or pH sensitive coating, or other chemically sensitive coating that provides for dissolution in a controlled fashion and allows one to activate the device when desired. Coatings that survive the stomach but dissolve in the intestine are also of interest, e.g., where one desires to delay activation until the device leaves the stomach. An example of such a coating is a polymer that is insoluble at low pH, but becomes soluble at a higher pH. Also of interest are pharmaceutical formulation protective coatings, e.g., a gel cap liquid protective coating that prevents the circuit from being activated by liquid of the gel cap.


Identifiers of interest include two dissimilar electrochemical materials, which act similar to the electrodes (e.g., anode and cathode) of a power source. The reference to an electrode or anode or cathode are used here merely as illustrative examples. The scope of the present invention is not limited by the label used and includes the aspect wherein the voltage potential is created between two dissimilar materials. Thus, when reference is made to an electrode, anode, or cathode it is intended as a reference to a voltage potential created between two dissimilar materials.


When the materials are exposed and come into contact with the body fluid, such as stomach acid or other types of fluid (either alone or in combination with a dried conductive medium precursor), a potential difference, that is, a voltage, is generated between the electrodes as a result of the respective oxidation and reduction reactions incurred to the two electrode materials. A voltaic cell, or battery, can thereby be produced. Accordingly, in aspects of the invention, such power supplies are configured such that when the two dissimilar materials are exposed to the target site, e.g., the stomach, the digestive tract, etc., a voltage is generated.


In certain aspects, one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage output of the battery. Non-metals that may be used as doping agents in certain aspects include, but are not limited to: sulfur, iodine and the like.


It is to be understood that this invention is not limited to particular embodiments or aspects described and, as such, may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.


Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.


All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.


It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


As will be apparent to those of skill in the art upon reading this disclosure, each of the individual aspects described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several aspects without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.


Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.


Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and aspects of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary aspects shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.

Claims
  • 1. A device comprising a partial power source for communication, the device comprising: a support structure;a layer of adhesion material deposited onto a first location of the support structure, wherein the layer of adhesion material defines a plurality of holes, and the support structure remains a solid and continuous support material underneath each of the plurality of holes;a first material deposited onto the layer of adhesion material and over the plurality of holes such that the first material covers the plurality of holes, wherein the first material adheres to the layer of adhesion material;a layer of transition material deposited onto a second location of the support structure; anda second material deposited onto the layer of transition material, wherein the first material and the second material are configured to generate a voltage potential difference when the first material and the second material come into contact with a conducting fluid.
  • 2. The device of claim 1, wherein the layer of adhesion material comprises a layer of gold.
  • 3. The device of claim 1, wherein a surface of the adhesion material is roughened to enhance adhesion property.
  • 4. The device of claim 1, wherein the support structure is a silicon based material.
  • 5. The device of claim 1, wherein the first material is deposited via evaporating deposition using electron beams.
  • 6. The device of claim 1, wherein the layer of adhesion material is less than 100 microns thick and the first material is deposited via evaporating deposition using electron beams.
  • 7. A device comprising a partial power source for communication, the device comprising: a support structure; a layer of adhesion material deposited onto a first location of the support structure, wherein the layer of adhesion material defines a plurality of holes;a first material deposited onto the layer of adhesion material and over the plurality of holes such that the first material covers the plurality of holes, wherein the first material adheres to the layer of adhesion material;a layer of transition material deposited onto a second location of the support structure; anda second material deposited onto the layer of transition material, wherein the first material and the second material are configured to generate a voltage potential difference when the first material and the second material come into contact with a conducting fluid,wherein the plurality of holes are confined to a center region of the layer of adhesion material such that each edge of the first material is not positioned over any hole of the plurality of holes when the first material adheres to the layer of adhesion material.
  • 8. The device of claim 7, wherein the layer of adhesion material comprises a layer of gold.
  • 9. The device of claim 7, wherein a surface of the adhesion material is roughened to enhance adhesion property.
  • 10. The device of claim 7, wherein the support structure is a silicon based material.
  • 11. The device of claim 7, wherein the first material is deposited via evaporating deposition using electron beams.
  • 12. The device of claim 7, wherein the layer of adhesion material is less than 100 microns thick and the first material is deposited via evaporating deposition using electron beams.
  • 13. A device comprising a partial power source for communication, the device comprising: a support structure; a layer of adhesion material deposited onto a first location of the support structure, wherein the layer of adhesion material defines a plurality of holes;a first material deposited onto the layer of adhesion material and over the plurality of holes such that the first material covers the plurality of holes, wherein the first material adheres to the layer of adhesion material and the plurality of holes is configured to enhance adhesion of the first material to the layer of adhesion material;a layer of transition material deposited onto a second location of the support structure; anda second material deposited onto the layer of transition material, wherein the first material and the second material a voltage potential difference when the first material and the second material come into contact with a conducting fluid.
  • 14. The device of claim 13, wherein the layer of adhesion material comprises a layer of gold.
  • 15. The device of claim 13, wherein a surface of the adhesion material is roughened to enhance adhesion property.
  • 16. The device of claim 13, wherein the support structure is a silicon based material.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. patent application Ser. No. 13/180,525, filed on Jul. 11, 2011 and entitled “Communication System with Enhanced Partial Power and Method of Manufacturing Same”, which is related to U.S. patent application Ser. No. 12/564,017, filed on Sep. 21, 2009 and entitled “Communication System with Partial Power Source”, published on Apr. 1, 2010 as U.S. Publication No. US2010-0081894A1, which is a continuation-in-part application of U.S. patent application Ser. No. 11/912,475 filed Jun. 23, 2008 and entitled “Pharma-Informatics System”, published on Nov. 20, 2008 as U.S. Publication No. 2008-0284599A1 which application is a 371 application of PCT Application No. PCT/US06/16370 filed Apr. 28, 2006 and entitled “Pharma-Informatics System”; which application pursuant to 35 U.S.C. § 119 (e), claims priority to the filing dates of: U.S. Provisional Patent Application Ser. No. 60/676,145 filed Apr. 28, 2005 and entitled “Pharma-Informatics System”; U.S. Provisional Patent Application Ser. No. 60/694,078, filed Jun. 24, 2005, and entitled “Pharma-Informatics System”; U.S. Provisional Patent Application Ser. No. 60/713,680 filed Sep. 1, 2005 and entitled “Medical Diagnostic And Treatment Platform Using Near-Field Wireless Communication Of Information Within A Patient's Body”; and U.S. Provisional Patent Application Ser. No. 60/790,335 filed Apr. 7, 2006 and entitled “Pharma-Informatics System”; the disclosures of which are herein incorporated by reference. This application is related to the following U.S. Applications filed concurrently herewith, the disclosures of which are incorporated herein by reference: U.S. application Ser. No. 13/180,516, filed Jul. 11, 2011 entitled COMMUNICATION SYSTEM WITH REMOTE ACTIVATION; U.S. application Ser. No. 13/180,498, filed Jul. 11, 2011, entitled COMMUNICATION SYSTEM WITH MULTIPLE TYPES OF POWER; U.S. application Ser. No. 13/180,539, filed Jul. 11, 2011, entitled COMMUNICATION SYSTEM USING AN IMPLANTABLE DEVICE; U.S. application Ser. No. 13/180,538, filed Jul. 11, 2011, entitled COMMUNICATION SYSTEM USING POLYPHARMACY CO-PACKAGED MEDICATION DOSING UNIT; and U.S. application Ser. No. 13/180,507, filed Jul. 11, 2011, entitled COMMUNICATION SYSTEM INCORPORATED IN AN INGESTIBLE PRODUCT.

US Referenced Citations (990)
Number Name Date Kind
1548459 Hammer Aug 1925 A
2587158 Hofberg Feb 1952 A
2973555 Schwepke Mar 1961 A
3048526 Boswell Aug 1962 A
3079824 Schott Mar 1963 A
3096248 Rudzki Jul 1963 A
3176399 Marino et al. Apr 1965 A
3589943 Grubb et al. Jun 1971 A
3607788 Adolph Sep 1971 A
3642008 Bolduc Feb 1972 A
3679480 Brown et al. Jul 1972 A
3682160 Murata Aug 1972 A
3719183 Schwartz Mar 1973 A
3799802 Schneble, Jr. et al. Mar 1974 A
3828766 Krasnow Aug 1974 A
3837339 Aisenberg et al. Sep 1974 A
3849041 Knapp Nov 1974 A
3893111 Cotter Jul 1975 A
3944064 Bashaw et al. Mar 1976 A
3967202 Batz Jun 1976 A
3989050 Buchalter Nov 1976 A
4017856 Wiegand Apr 1977 A
4055178 Harrigan Oct 1977 A
4062750 Butler Dec 1977 A
4077397 Ellis Mar 1978 A
4077398 Ellis Mar 1978 A
4082087 Howson Apr 1978 A
4090752 Long May 1978 A
4106348 Auphan Aug 1978 A
4129125 Lester Dec 1978 A
4139589 Beringer et al. Feb 1979 A
4143770 Grimmell et al. Mar 1979 A
4166453 McClelland Sep 1979 A
4239046 Ong Dec 1980 A
4251795 Shibasaki et al. Feb 1981 A
4269189 Abraham May 1981 A
4331654 Morris May 1982 A
4345588 Widder et al. Aug 1982 A
4418697 Tama Dec 1983 A
4425117 Hugemann Jan 1984 A
4439196 Higuchi Mar 1984 A
4494950 Fischell Jan 1985 A
4559950 Vaughan Dec 1985 A
4564363 Bagnall et al. Jan 1986 A
4635641 Hoffman Jan 1987 A
4654165 Eisenber Mar 1987 A
4663250 Ong et al. May 1987 A
4669479 Dunseath Jun 1987 A
4687660 Baker et al. Aug 1987 A
4725997 Urquhart et al. Feb 1988 A
4749575 Rotman et al. Jun 1988 A
4763659 Dunseath Aug 1988 A
4767627 Caldwell et al. Aug 1988 A
4775536 Patell Oct 1988 A
4784162 Ricks Nov 1988 A
4793825 Benjamin et al. Dec 1988 A
4814181 Jordan et al. Mar 1989 A
4844076 Lesho Jul 1989 A
4847090 Della Posta et al. Jul 1989 A
4876093 Theeuwes et al. Oct 1989 A
4891223 Ambegaonakar et al. Jan 1990 A
4896261 Nolan Jan 1990 A
4900552 Sanvordeker et al. Feb 1990 A
4975230 Pinkhasov Dec 1990 A
4987897 Funke Jan 1991 A
5000957 Eckenhoff et al. Mar 1991 A
5016634 Vock et al. May 1991 A
5018335 Yamamoto et al. May 1991 A
5079006 Urguhart Jan 1992 A
5110441 Kinlen et al. May 1992 A
5160885 Hannam et al. Nov 1992 A
5167626 Casper Dec 1992 A
5176626 Soehendra Jan 1993 A
5187723 Mueller Feb 1993 A
5213738 Hampton et al. May 1993 A
5218343 Stobbe et al. Jun 1993 A
5261402 DiSabito Nov 1993 A
5263481 Axelgaard et al. Nov 1993 A
5273066 Graham et al. Dec 1993 A
5279607 Schentag et al. Jan 1994 A
5281287 Lloyd Jan 1994 A
5283136 Peled et al. Feb 1994 A
5288564 Klein Feb 1994 A
5305745 Zacouto Apr 1994 A
5310301 Aono May 1994 A
5318557 Gross Jun 1994 A
5331953 Andersson et al. Jul 1994 A
5394882 Mawhinney Mar 1995 A
5395366 D'Andrea et al. Mar 1995 A
5436091 Shackle et al. Jul 1995 A
5443461 Atkinson et al. Aug 1995 A
5443843 Curatolo et al. Aug 1995 A
5458141 Neil et al. Oct 1995 A
5458994 Nesselbeck et al. Oct 1995 A
5485841 Watkin et al. Jan 1996 A
5506248 Nikfar et al. Apr 1996 A
5551020 Flax et al. Aug 1996 A
5567210 Bates et al. Oct 1996 A
5596302 Mastrocola et al. Jan 1997 A
5600548 Nguyen et al. Feb 1997 A
5603363 Nelson Feb 1997 A
5634468 Platt Jun 1997 A
5645063 Straka et al. Jul 1997 A
5659247 Clements Aug 1997 A
5703463 Smith Dec 1997 A
5705189 Lehmann et al. Jan 1998 A
5724432 Bouvet et al. Mar 1998 A
5738708 Peachey et al. Apr 1998 A
5740811 Hedberg Apr 1998 A
5757326 Koyama et al. May 1998 A
5772575 Lesinski et al. Jun 1998 A
5792048 Schaefer Aug 1998 A
5802467 Salazar Sep 1998 A
5833716 Bar-Or Nov 1998 A
5842324 Grosskopf et al. Dec 1998 A
5845265 Woolston Dec 1998 A
5862803 Besson Jan 1999 A
5868136 Fox Feb 1999 A
5914132 Kelm et al. Jun 1999 A
5914701 Gersheneld et al. Jun 1999 A
5925030 Gross et al. Jul 1999 A
5957854 Besson et al. Sep 1999 A
5963132 Yoakum et al. Oct 1999 A
5974124 Schlueter, Jr. et al. Oct 1999 A
5981166 Mandecki Nov 1999 A
5999846 Pardey et al. Dec 1999 A
6018229 Mitchell et al. Jan 2000 A
6038464 Axelgaard et al. Mar 2000 A
6042710 Dubrow Mar 2000 A
6047203 Sackner Apr 2000 A
6068465 Wilson May 2000 A
6068589 Neukermans May 2000 A
6076016 Feierbach et al. Jun 2000 A
6081734 Batz Jun 2000 A
6091975 Daddona et al. Jul 2000 A
6095985 Raymond et al. Aug 2000 A
6115636 Ryan Sep 2000 A
6122351 Schlueter, Jr. et al. Sep 2000 A
6141592 Pauly Oct 2000 A
6149940 Maggi et al. Nov 2000 A
6200265 Walsh et al. Mar 2001 B1
6206702 Hayden et al. Mar 2001 B1
6217744 Crosby Apr 2001 B1
6231593 Meserol May 2001 B1
6245057 Sieben et al. Jun 2001 B1
6269058 Yamanoi et al. Jul 2001 B1
6285897 Kilcoyne et al. Sep 2001 B1
6287252 Lugo Sep 2001 B1
6288629 Cofino et al. Sep 2001 B1
6289238 Besson et al. Sep 2001 B1
6315719 Rode et al. Nov 2001 B1
6317714 Del Castillo Nov 2001 B1
6342774 Kreisinger et al. Jan 2002 B1
6344824 Takasugi et al. Feb 2002 B1
6358202 Arent Mar 2002 B1
6364834 Reuss Apr 2002 B1
6366206 Ishikawa et al. Apr 2002 B1
6371927 Brune Apr 2002 B1
6374670 Spelman Apr 2002 B1
6380858 Yarin et al. Apr 2002 B1
6390088 Noehl et al. May 2002 B1
6394997 Lemelson May 2002 B1
6426863 Munshi Jul 2002 B1
6432292 Pinto et al. Aug 2002 B1
6440069 Raymond et al. Aug 2002 B1
6441747 Khair Aug 2002 B1
6453199 Kobozev Sep 2002 B1
6477424 Thompson et al. Nov 2002 B1
6496705 Ng et al. Dec 2002 B1
6526315 Inagawa Feb 2003 B1
6531026 Takeichi et al. Mar 2003 B1
6544174 West Apr 2003 B2
6547994 Monkhouse et al. Apr 2003 B1
6564079 Cory May 2003 B1
6567685 Takamori et al. May 2003 B2
6572636 Hagen et al. Jun 2003 B1
6577893 Besson et al. Jun 2003 B1
6579231 Phipps Jun 2003 B1
6595929 Stivoric Jul 2003 B2
6599284 Faour et al. Jul 2003 B2
6602518 Seielstad et al. Aug 2003 B2
6605038 Teller Aug 2003 B1
6609018 Cory Aug 2003 B2
6612984 Kerr Sep 2003 B1
6632175 Marshall Oct 2003 B1
6632216 Houzego et al. Oct 2003 B2
6635279 Kolter et al. Oct 2003 B2
6643541 Mok et al. Nov 2003 B2
6654638 Sweeney Nov 2003 B1
6663846 McCombs Dec 2003 B1
6673474 Yamamoto Jan 2004 B2
6680923 Leon Jan 2004 B1
6689117 Sweeney et al. Feb 2004 B2
6694161 Mehrotra Feb 2004 B2
6704602 Berg et al. Mar 2004 B2
6720923 Hayward et al. Apr 2004 B1
6738671 Christophersom et al. May 2004 B2
6740033 Olejniczak et al. May 2004 B1
6745082 Axelgaard et al. Jun 2004 B2
6755783 Cosentino Jun 2004 B2
6757523 Fry Jun 2004 B2
6759968 Zierolf Jul 2004 B2
6767200 Sowden et al. Jul 2004 B2
6773429 Sheppard et al. Aug 2004 B2
6800060 Marshall Oct 2004 B2
6801137 Eggers et al. Oct 2004 B2
6816794 Alvi Nov 2004 B2
6822554 Vrijens et al. Nov 2004 B2
6824512 Warkentin et al. Nov 2004 B2
6836862 Erekson et al. Dec 2004 B1
6839659 Tarassenko et al. Jan 2005 B2
6840904 Goldberg Jan 2005 B2
6842636 Perrault Jan 2005 B2
6845272 Thomsen Jan 2005 B1
6864780 Doi Mar 2005 B2
6879810 Bouet Apr 2005 B2
6888337 Sawyers May 2005 B2
6889165 Lind et al. May 2005 B2
6909878 Haller Jun 2005 B2
6922592 Thompson et al. Jul 2005 B2
6928370 Anuzis et al. Aug 2005 B2
6929636 Von Alten Aug 2005 B1
6937150 Medema Aug 2005 B2
6942616 Kerr Sep 2005 B2
6942770 Cai et al. Sep 2005 B2
6946156 Bunick Sep 2005 B2
6951536 Yokoi Oct 2005 B2
6957107 Rogers et al. Oct 2005 B2
6958603 Kondo Oct 2005 B2
6960617 Omidian et al. Nov 2005 B2
6968153 Heinonen Nov 2005 B1
6977511 Patel et al. Dec 2005 B2
6982094 Sowden Jan 2006 B2
6987965 Ng et al. Jan 2006 B2
6990082 Zehavi et al. Jan 2006 B1
7002476 Rapchak Feb 2006 B2
7004395 Koenck Feb 2006 B2
7009634 Iddan et al. Mar 2006 B2
7009946 Kardach Mar 2006 B1
7013162 Gorsuch Mar 2006 B2
7016648 Haller Mar 2006 B2
7020508 Stivoric Mar 2006 B2
7024248 Penner et al. Apr 2006 B2
7031745 Shen Apr 2006 B2
7031857 Tarassenko et al. Apr 2006 B2
7039453 Mullick May 2006 B2
7044911 Drinan et al. May 2006 B2
7046649 Awater et al. May 2006 B2
7061236 Britton Jun 2006 B2
7083578 Lewkowicz Aug 2006 B2
7116252 Teraguchi Oct 2006 B2
7118531 Krill Oct 2006 B2
7122143 Sowden et al. Oct 2006 B2
7127300 Mazar et al. Oct 2006 B2
7146228 Nielsen Dec 2006 B2
7146449 Do et al. Dec 2006 B2
7149581 Goedeke et al. Dec 2006 B2
7154071 Sattler et al. Dec 2006 B2
7155232 Godfrey et al. Dec 2006 B2
7160258 Imran Jan 2007 B2
7164942 Avrahami Jan 2007 B2
7171166 Ng et al. Jan 2007 B2
7171177 Park et al. Jan 2007 B2
7171259 Rytky Jan 2007 B2
7176784 Gilbert et al. Feb 2007 B2
7187960 Abreu Mar 2007 B2
7188199 Leung et al. Mar 2007 B2
7188767 Penuela Mar 2007 B2
7194038 Inkinen Mar 2007 B1
7196495 Burcham Mar 2007 B1
7206630 Tarler Apr 2007 B1
7209790 Thompson et al. Apr 2007 B2
7215660 Perlman May 2007 B2
7215991 Besson May 2007 B2
7218967 Bergelson May 2007 B2
7231451 Law Jun 2007 B2
7243118 Lou Jul 2007 B2
7246521 Kim Jul 2007 B2
7249212 Do Jul 2007 B2
7252792 Perrault Aug 2007 B2
7253716 Lovoi et al. Aug 2007 B2
7261690 Teller Aug 2007 B2
7270633 Goscha Sep 2007 B1
7273454 Raymond et al. Sep 2007 B2
7289855 Nghiem Oct 2007 B2
7291497 Holmes Nov 2007 B2
7292139 Mazar et al. Nov 2007 B2
7294105 Islam Nov 2007 B1
7311665 Hawthorne Dec 2007 B2
7313163 Liu Dec 2007 B2
7317378 Jarvis et al. Jan 2008 B2
7318808 Tarassenko et al. Jan 2008 B2
7336929 Yasuda Feb 2008 B2
7342895 Serpa Mar 2008 B2
7346380 Axelgaard et al. Mar 2008 B2
7349722 Witkowski et al. Mar 2008 B2
7352998 Palin Apr 2008 B2
7353258 Washburn Apr 2008 B2
7357891 Yang et al. Apr 2008 B2
7359674 Markki Apr 2008 B2
7366558 Virtanen et al. Apr 2008 B2
7368190 Heller et al. May 2008 B2
7368191 Andelman et al. May 2008 B2
7373196 Ryu et al. May 2008 B2
7375739 Robbins May 2008 B2
7376435 McGowan May 2008 B2
7382247 Welch et al. Jun 2008 B2
7382263 Danowski et al. Jun 2008 B2
7387607 Holt Jun 2008 B2
7388903 Godfrey et al. Jun 2008 B2
7389088 Kim Jun 2008 B2
7392015 Farlow Jun 2008 B1
7395106 Ryu et al. Jul 2008 B2
7396330 Banet Jul 2008 B2
7404968 Abrams et al. Jul 2008 B2
7413544 Kerr Aug 2008 B2
7414534 Kroll et al. Aug 2008 B1
7414543 Rye et al. Aug 2008 B2
7415242 Ngan Aug 2008 B1
7424268 Diener Sep 2008 B2
7424319 Muehlsteff Sep 2008 B2
7427266 Ayer et al. Sep 2008 B2
7442164 Berrang et al. Oct 2008 B2
7443290 Takiguchi Oct 2008 B2
7458887 Kurosawa Dec 2008 B2
7469838 Brooks et al. Dec 2008 B2
7471665 Perlman Dec 2008 B2
7471992 Schmidt et al. Dec 2008 B2
7492128 Shen Feb 2009 B2
7499674 Salokannel Mar 2009 B2
7510121 Koenck Mar 2009 B2
7512448 Malick Mar 2009 B2
7515043 Welch Apr 2009 B2
7519416 Sula et al. Apr 2009 B2
7523756 Minai Apr 2009 B2
7525426 Edelstein Apr 2009 B2
7527807 Choi et al. May 2009 B2
7537590 Santini, Jr. et al. May 2009 B2
7539533 Tran May 2009 B2
7542878 Nanikashvili Jun 2009 B2
7547278 Miyazaki et al. Jun 2009 B2
7551590 Haller Jun 2009 B2
7554452 Cole Jun 2009 B2
7558620 Ishibashi Jul 2009 B2
7575005 Mumford Aug 2009 B2
7616111 Covannon Nov 2009 B2
7617001 Penner et al. Nov 2009 B2
7626387 Adachi Dec 2009 B2
7639473 Hsu et al. Dec 2009 B2
7640802 King et al. Jan 2010 B2
7645262 Greenberg et al. Jan 2010 B2
7647112 Tracey Jan 2010 B2
7647185 Tarassenko et al. Jan 2010 B2
7653031 Godfrey et al. Jan 2010 B2
7672714 Kuo Mar 2010 B2
7673679 Harrison et al. Mar 2010 B2
7678043 Gilad Mar 2010 B2
7686839 Parker Mar 2010 B2
7697994 VanDanacker et al. Apr 2010 B2
7720036 Sadri May 2010 B2
7729776 Von Arx et al. Jun 2010 B2
7733224 Tran Jun 2010 B2
7736318 Costentino Jun 2010 B2
7756587 Penner et al. Jul 2010 B2
7760104 Asp Jul 2010 B2
7782991 Sobchak et al. Aug 2010 B2
7796043 Euliano Sep 2010 B2
7797033 D'Andrea et al. Sep 2010 B2
7809399 Lu Oct 2010 B2
7844341 Von Arx et al. Nov 2010 B2
7881799 Greenberg et al. Feb 2011 B2
7975587 Schneider Jul 2011 B2
7978064 Zdeblick et al. Jul 2011 B2
7983189 Bugenhagen Jul 2011 B2
8036731 Kimchy et al. Oct 2011 B2
8036748 Zdeblick et al. Oct 2011 B2
8054047 Chen et al. Nov 2011 B2
8054140 Fleming et al. Nov 2011 B2
8055334 Savage et al. Nov 2011 B2
8082919 Brunnberg et al. Dec 2011 B2
8119045 Schmidt et al. Feb 2012 B2
8131376 Faraji et al. Mar 2012 B1
8177611 Kang May 2012 B2
8185191 Shapiro et al. May 2012 B1
8185646 Headley May 2012 B2
8200320 Kovacs Jun 2012 B2
8207731 Moskalenko Jun 2012 B2
8224596 Agrawal et al. Jul 2012 B2
8253586 Matak Aug 2012 B1
8254853 Rofougaran Aug 2012 B2
8271146 Heber et al. Sep 2012 B2
8298574 Tsabari et al. Oct 2012 B2
8343068 Najafi et al. Jan 2013 B2
8374698 Ok et al. Feb 2013 B2
8389003 Mintchev et al. Mar 2013 B2
8404275 Habboushe Mar 2013 B2
8425492 Herbert et al. Apr 2013 B2
8443214 Lee et al. May 2013 B2
8454528 Yuen et al. Jun 2013 B2
8532776 Greenberg et al. Sep 2013 B2
8540664 Robertson et al. Sep 2013 B2
8547248 Zdeblick et al. Oct 2013 B2
8558563 Zdeblick Oct 2013 B2
8564432 Covannon et al. Oct 2013 B2
8597186 Hafezi et al. Dec 2013 B2
8634838 Hellwig et al. Jan 2014 B2
8647358 Brister et al. Feb 2014 B2
8660645 Stevenson et al. Feb 2014 B2
8668643 Kinast Mar 2014 B2
8685451 Toneguzzo et al. Apr 2014 B2
8697057 Van Epps et al. Apr 2014 B2
8698006 Bealka et al. Apr 2014 B2
8758237 Sherman et al. Jun 2014 B2
8784308 Duck et al. Jul 2014 B2
8802183 Frank et al. Aug 2014 B2
8816847 Zdeblick et al. Aug 2014 B2
8836513 Hafezi et al. Sep 2014 B2
8838217 Myr Sep 2014 B2
8858432 Robertson Oct 2014 B2
8908943 Berry et al. Dec 2014 B2
8912908 Berkman et al. Dec 2014 B2
8926509 Magar et al. Jan 2015 B2
8932221 Colliou et al. Jan 2015 B2
8945005 Hafezi et al. Feb 2015 B2
8951234 Hafezi et al. Feb 2015 B2
8989837 Weinstein et al. Mar 2015 B2
9031658 Chiao et al. May 2015 B2
9088168 Mach et al. Jul 2015 B2
9107806 Hafezi et al. Aug 2015 B2
9119918 Robertson et al. Sep 2015 B2
9158890 Meredith et al. Oct 2015 B2
9189941 Eschelman et al. Nov 2015 B2
9226663 Fei Jan 2016 B2
9226679 Balda Jan 2016 B2
9268909 Jani et al. Feb 2016 B2
9270025 Robertson et al. Feb 2016 B2
9271897 Costello et al. Mar 2016 B2
9277864 Yang et al. Mar 2016 B2
9415010 Hafezi et al. Aug 2016 B2
9433371 Hafezi et al. Sep 2016 B2
9439599 Thompson et al. Sep 2016 B2
9517012 Lane et al. Dec 2016 B2
9599679 Taylor et al. Mar 2017 B2
9741975 Laulicht et al. Aug 2017 B2
9756874 Arne et al. Sep 2017 B2
9968284 Vidalis et al. May 2018 B2
20010027331 Thompson Oct 2001 A1
20010044588 Mault Nov 2001 A1
20010051766 Gazdinski Dec 2001 A1
20020002326 Causey et al. Jan 2002 A1
20020026111 Ackerman Feb 2002 A1
20020032384 Raymond et al. Mar 2002 A1
20020032385 Raymond et al. Mar 2002 A1
20020040278 Anuzis et al. Apr 2002 A1
20020077620 Sweeney et al. Jun 2002 A1
20020099423 Berg et al. Jul 2002 A1
20020128934 Shaer Sep 2002 A1
20020132226 Nair Sep 2002 A1
20020136744 McGlynn et al. Sep 2002 A1
20020179921 Cohn Dec 2002 A1
20020192159 Reitberg Dec 2002 A1
20020193669 Glukhovsky Dec 2002 A1
20020198470 Imran et al. Dec 2002 A1
20030017826 Fishman et al. Jan 2003 A1
20030023150 Yokoi et al. Jan 2003 A1
20030028226 Thompson Feb 2003 A1
20030062551 Chen et al. Apr 2003 A1
20030065536 Hansen Apr 2003 A1
20030076179 Branch et al. Apr 2003 A1
20030083559 Thompson May 2003 A1
20030091625 Hariharan et al. May 2003 A1
20030126593 Mault Jul 2003 A1
20030130714 Nielsen et al. Jul 2003 A1
20030135128 Suffin et al. Jul 2003 A1
20030135392 Vrijens et al. Jul 2003 A1
20030152622 Louie-Helm et al. Aug 2003 A1
20030158466 Lynn et al. Aug 2003 A1
20030158756 Abramson Aug 2003 A1
20030162556 Libes Aug 2003 A1
20030164401 Andreasson et al. Sep 2003 A1
20030167000 Mullick et al. Sep 2003 A1
20030171791 KenKnight Sep 2003 A1
20030171898 Tarassenko et al. Sep 2003 A1
20030181788 Yokoi et al. Sep 2003 A1
20030185286 Yuen Oct 2003 A1
20030187337 Tarassenko et al. Oct 2003 A1
20030187338 Say et al. Oct 2003 A1
20030195403 Berner et al. Oct 2003 A1
20030213495 Fujita et al. Nov 2003 A1
20030214579 Iddan Nov 2003 A1
20030216622 Meron et al. Nov 2003 A1
20030216625 Phipps Nov 2003 A1
20030216666 Ericson et al. Nov 2003 A1
20030216729 Marchitto Nov 2003 A1
20030219484 Sowden et al. Nov 2003 A1
20030232895 Omidian et al. Dec 2003 A1
20040008123 Carrender et al. Jan 2004 A1
20040018476 LaDue Jan 2004 A1
20040034295 Salganicoff Feb 2004 A1
20040049245 Gass Mar 2004 A1
20040073095 Causey et al. Apr 2004 A1
20040073454 Urquhart et al. Apr 2004 A1
20040077995 Ferek-Petric Apr 2004 A1
20040082982 Gord et al. Apr 2004 A1
20040087839 Raymond et al. May 2004 A1
20040092801 Drakulic May 2004 A1
20040106859 Say et al. Jun 2004 A1
20040115507 Potter et al. Jun 2004 A1
20040115517 Fukuda et al. Jun 2004 A1
20040117062 Bonney et al. Jun 2004 A1
20040121015 Chidlaw et al. Jun 2004 A1
20040148140 Tarassenko et al. Jul 2004 A1
20040153007 Harris Aug 2004 A1
20040167226 Serafini Aug 2004 A1
20040167465 Mihai et al. Aug 2004 A1
20040167801 Say et al. Aug 2004 A1
20040193020 Chiba Sep 2004 A1
20040193029 Gluhovsky Sep 2004 A1
20040193446 Mayer et al. Sep 2004 A1
20040199222 Sun et al. Oct 2004 A1
20040215084 Shimizu et al. Oct 2004 A1
20040218683 Batra Nov 2004 A1
20040220643 Schmidt Nov 2004 A1
20040224644 Wu Nov 2004 A1
20040225199 Evanyk Nov 2004 A1
20040253304 Gross et al. Dec 2004 A1
20040258571 Lee et al. Dec 2004 A1
20040259899 Sanghvi et al. Dec 2004 A1
20040260154 Sidelnik Dec 2004 A1
20050003074 Brown et al. Jan 2005 A1
20050017841 Doi Jan 2005 A1
20050020887 Goldberg Jan 2005 A1
20050021370 Riff Jan 2005 A1
20050024198 Ward Feb 2005 A1
20050027205 Tarassenko et al. Feb 2005 A1
20050038321 Fujita et al. Feb 2005 A1
20050043634 Yokoi et al. Feb 2005 A1
20050043894 Fernandez Feb 2005 A1
20050054897 Hashimoto et al. Mar 2005 A1
20050055014 Coppeta et al. Mar 2005 A1
20050062644 Leci Mar 2005 A1
20050065407 Nakamura et al. Mar 2005 A1
20050070778 Lackey Mar 2005 A1
20050075145 Dvorak et al. Apr 2005 A1
20050090753 Goor et al. Apr 2005 A1
20050092108 Andermo May 2005 A1
20050096514 Starkebaum May 2005 A1
20050096562 Delalic et al. May 2005 A1
20050101843 Quinn May 2005 A1
20050101872 Sattler May 2005 A1
20050115561 Stahmann et al. Jun 2005 A1
20050116820 Goldreich Jun 2005 A1
20050117389 Worledge Jun 2005 A1
20050121322 Say et al. Jun 2005 A1
20050131281 Ayer et al. Jun 2005 A1
20050143623 Kojima Jun 2005 A1
20050146594 Nakatani et al. Jul 2005 A1
20050148883 Boesen Jul 2005 A1
20050154428 Bruinsma Jul 2005 A1
20050156709 Gilbert et al. Jul 2005 A1
20050165323 Montgomery Jul 2005 A1
20050177069 Takizawa Aug 2005 A1
20050182389 LaPorte Aug 2005 A1
20050187789 Hatlestad et al. Aug 2005 A1
20050192489 Marshall Sep 2005 A1
20050197680 DelMain et al. Sep 2005 A1
20050208251 Aisenbrey Sep 2005 A1
20050228268 Cole Oct 2005 A1
20050234307 Heinonen Oct 2005 A1
20050240305 Bogash et al. Oct 2005 A1
20050245794 Dinsmoor Nov 2005 A1
20050259768 Yang et al. Nov 2005 A1
20050261559 Mumford Nov 2005 A1
20050267556 Shuros et al. Dec 2005 A1
20050267756 Schultz et al. Dec 2005 A1
20050277912 John Dec 2005 A1
20050277999 Strother et al. Dec 2005 A1
20050279054 Mauze et al. Dec 2005 A1
20050280539 Pettus Dec 2005 A1
20050285746 Sengupta Dec 2005 A1
20050288594 Lewkowicz et al. Dec 2005 A1
20060001496 Abrosimov et al. Jan 2006 A1
20060028727 Moon et al. Feb 2006 A1
20060036134 Tarassenko et al. Feb 2006 A1
20060058602 Kwiatkowski et al. Mar 2006 A1
20060061472 Lovoi et al. Mar 2006 A1
20060065713 Kingery Mar 2006 A1
20060068006 Begleiter Mar 2006 A1
20060074283 Henderson Apr 2006 A1
20060074319 Barnes et al. Apr 2006 A1
20060078765 Yang et al. Apr 2006 A1
20060095091 Drew May 2006 A1
20060095093 Bettesh et al. May 2006 A1
20060100533 Han May 2006 A1
20060109058 Keating May 2006 A1
20060110962 Powell May 2006 A1
20060122474 Teller et al. Jun 2006 A1
20060122494 Bouchoucha Jun 2006 A1
20060122667 Chavan et al. Jun 2006 A1
20060129060 Lee et al. Jun 2006 A1
20060136266 Tarassenko et al. Jun 2006 A1
20060142648 Banet Jun 2006 A1
20060145876 Kimura Jul 2006 A1
20060148254 McLean Jul 2006 A1
20060149339 Burnes Jul 2006 A1
20060155174 Glukhovsky et al. Jul 2006 A1
20060155183 Kroecker Jul 2006 A1
20060161225 Sormann et al. Jul 2006 A1
20060179949 Kim Aug 2006 A1
20060183993 Horn Aug 2006 A1
20060184092 Atanasoska et al. Aug 2006 A1
20060204738 Dubrow et al. Sep 2006 A1
20060210626 Spaeder Sep 2006 A1
20060216603 Choi Sep 2006 A1
20060218011 Walker Sep 2006 A1
20060235489 Drew Oct 2006 A1
20060243288 Kim et al. Nov 2006 A1
20060247505 Siddiqui Nov 2006 A1
20060253005 Drinan Nov 2006 A1
20060270346 Ibrahim Nov 2006 A1
20060273882 Posamentier Dec 2006 A1
20060276702 McGinnis Dec 2006 A1
20060280227 Pinkney Dec 2006 A1
20060282001 Noel Dec 2006 A1
20060289640 Mercure Dec 2006 A1
20060293607 Alt Dec 2006 A1
20070000776 Karube et al. Jan 2007 A1
20070002038 Suzuki Jan 2007 A1
20070006636 King et al. Jan 2007 A1
20070008113 Spoonhower et al. Jan 2007 A1
20070016089 Fischell et al. Jan 2007 A1
20070027386 Such Feb 2007 A1
20070027388 Chou Feb 2007 A1
20070029195 Li et al. Feb 2007 A1
20070038054 Zhou Feb 2007 A1
20070049339 Barak et al. Mar 2007 A1
20070055098 Shimizu et al. Mar 2007 A1
20070060797 Ball Mar 2007 A1
20070060800 Drinan et al. Mar 2007 A1
20070066929 Ferren et al. Mar 2007 A1
20070073353 Rooney et al. Mar 2007 A1
20070096765 Kagan May 2007 A1
20070106346 Bergelson May 2007 A1
20070123772 Euliano May 2007 A1
20070129622 Bourget Jun 2007 A1
20070130287 Kumar Jun 2007 A1
20070135803 Belson Jun 2007 A1
20070142721 Berner et al. Jun 2007 A1
20070156016 Betesh Jul 2007 A1
20070160789 Merical Jul 2007 A1
20070162089 Mosesov Jul 2007 A1
20070162090 Penner Jul 2007 A1
20070167495 Brown et al. Jul 2007 A1
20070167848 Kuo et al. Jul 2007 A1
20070173701 Al-Ali Jul 2007 A1
20070179347 Tarassenko et al. Aug 2007 A1
20070179371 Peyser et al. Aug 2007 A1
20070185393 Zhou Aug 2007 A1
20070191002 Ge Aug 2007 A1
20070196456 Stevens Aug 2007 A1
20070207793 Myer Sep 2007 A1
20070208233 Kovacs Sep 2007 A1
20070213659 Trovato et al. Sep 2007 A1
20070237719 Jones Oct 2007 A1
20070244370 Kuo et al. Oct 2007 A1
20070255198 Leong et al. Nov 2007 A1
20070255330 Lee Nov 2007 A1
20070270672 Hayter Nov 2007 A1
20070279217 Venkatraman Dec 2007 A1
20070282174 Sabatino Dec 2007 A1
20070282177 Pilz Dec 2007 A1
20070299480 Hill Dec 2007 A1
20080000804 Carey et al. Jan 2008 A1
20080014866 Lipowshi Jan 2008 A1
20080020037 Robertson et al. Jan 2008 A1
20080021519 DeGeest Jan 2008 A1
20080021521 Shah Jan 2008 A1
20080027679 Shklarski Jan 2008 A1
20080033273 Zhou Feb 2008 A1
20080038588 Lee Feb 2008 A1
20080039700 Drinan et al. Feb 2008 A1
20080045843 Tsuji et al. Feb 2008 A1
20080046038 Hill Feb 2008 A1
20080051647 Wu et al. Feb 2008 A1
20080051667 Goldreich Feb 2008 A1
20080058614 Banet Mar 2008 A1
20080062856 Feher Mar 2008 A1
20080065168 Bitton et al. Mar 2008 A1
20080074307 Boric-Lubecke Mar 2008 A1
20080077015 Botic-Lubecke Mar 2008 A1
20080077028 Schaldach et al. Mar 2008 A1
20080077188 Denker et al. Mar 2008 A1
20080091089 Guillory et al. Apr 2008 A1
20080091114 Min Apr 2008 A1
20080097549 Colbaugh Apr 2008 A1
20080097917 Dicks Apr 2008 A1
20080103440 Ferren et al. May 2008 A1
20080112885 Okunev et al. May 2008 A1
20080114224 Bandy et al. May 2008 A1
20080119705 Patel May 2008 A1
20080119716 Boric-Lubecke May 2008 A1
20080121825 Trovato et al. May 2008 A1
20080137566 Marholev Jun 2008 A1
20080139907 Rao et al. Jun 2008 A1
20080140403 Hughes et al. Jun 2008 A1
20080146871 Arneson et al. Jun 2008 A1
20080146889 Young Jun 2008 A1
20080146892 LeBeouf Jun 2008 A1
20080154104 Lamego Jun 2008 A1
20080166992 Ricordi Jul 2008 A1
20080175898 Jones et al. Jul 2008 A1
20080183245 Van Oort Jul 2008 A1
20080188837 Belsky et al. Aug 2008 A1
20080194912 Trovato et al. Aug 2008 A1
20080208009 Shklarski Aug 2008 A1
20080214901 Gehman Sep 2008 A1
20080214985 Yanaki Sep 2008 A1
20080243020 Chou Oct 2008 A1
20080249360 Li Oct 2008 A1
20080262320 Schaefer et al. Oct 2008 A1
20080262336 Ryu Oct 2008 A1
20080269664 Trovato et al. Oct 2008 A1
20080275312 Mosesov Nov 2008 A1
20080284599 Zdeblick et al. Nov 2008 A1
20080288027 Kroll Nov 2008 A1
20080294020 Sapounas Nov 2008 A1
20080299197 Toneguzzo et al. Dec 2008 A1
20080300572 Rankers Dec 2008 A1
20080303638 Nguyen Dec 2008 A1
20080306357 Korman Dec 2008 A1
20080306359 Zdeblick et al. Dec 2008 A1
20080306360 Robertson et al. Dec 2008 A1
20080311852 Hansen Dec 2008 A1
20080312522 Rowlandson Dec 2008 A1
20080316020 Robertson Dec 2008 A1
20090009330 Sakama et al. Jan 2009 A1
20090009332 Nunez et al. Jan 2009 A1
20090024045 Prakash Jan 2009 A1
20090024112 Edwards et al. Jan 2009 A1
20090030293 Cooper et al. Jan 2009 A1
20090030297 Miller Jan 2009 A1
20090034209 Joo Feb 2009 A1
20090043171 Rule Feb 2009 A1
20090047357 Tomohira et al. Feb 2009 A1
20090048498 Riskey Feb 2009 A1
20090062634 Say et al. Mar 2009 A1
20090062670 Sterling Mar 2009 A1
20090062730 Woo Mar 2009 A1
20090069642 Gao Mar 2009 A1
20090069655 Say et al. Mar 2009 A1
20090069656 Say et al. Mar 2009 A1
20090069657 Say et al. Mar 2009 A1
20090069658 Say et al. Mar 2009 A1
20090069724 Otto et al. Mar 2009 A1
20090076343 James Mar 2009 A1
20090076350 Bly et al. Mar 2009 A1
20090082645 Hafezi et al. Mar 2009 A1
20090087483 Sison Apr 2009 A1
20090088618 Ameson Apr 2009 A1
20090099435 Say et al. Apr 2009 A1
20090105561 Boydon et al. Apr 2009 A1
20090110148 Zhang Apr 2009 A1
20090112626 Talbot Apr 2009 A1
20090124871 Arshak May 2009 A1
20090124965 Greenberg et al. May 2009 A1
20090131774 Sweitzer May 2009 A1
20090135886 Robertson et al. May 2009 A1
20090142853 Warrington et al. Jun 2009 A1
20090149839 Hyde et al. Jun 2009 A1
20090157113 Marcotte Jun 2009 A1
20090157358 Kim Jun 2009 A1
20090161602 Matsumoto Jun 2009 A1
20090163789 Say et al. Jun 2009 A1
20090171180 Pering Jul 2009 A1
20090171420 Brown et al. Jul 2009 A1
20090173628 Say et al. Jul 2009 A1
20090177055 Say et al. Jul 2009 A1
20090177056 Say et al. Jul 2009 A1
20090177057 Say et al. Jul 2009 A1
20090177058 Say et al. Jul 2009 A1
20090177059 Say et al. Jul 2009 A1
20090177060 Say et al. Jul 2009 A1
20090177061 Say et al. Jul 2009 A1
20090177062 Say et al. Jul 2009 A1
20090177063 Say et al. Jul 2009 A1
20090177064 Say et al. Jul 2009 A1
20090177065 Say et al. Jul 2009 A1
20090177066 Say et al. Jul 2009 A1
20090182206 Najafi Jul 2009 A1
20090182207 Riskey et al. Jul 2009 A1
20090182212 Say et al. Jul 2009 A1
20090182213 Say et al. Jul 2009 A1
20090182214 Say et al. Jul 2009 A1
20090182215 Say et al. Jul 2009 A1
20090182388 Von Arx Jul 2009 A1
20090187088 Say et al. Jul 2009 A1
20090187089 Say et al. Jul 2009 A1
20090187090 Say et al. Jul 2009 A1
20090187091 Say et al. Jul 2009 A1
20090187092 Say et al. Jul 2009 A1
20090187093 Say et al. Jul 2009 A1
20090187094 Say et al. Jul 2009 A1
20090187095 Say et al. Jul 2009 A1
20090187381 King et al. Jul 2009 A1
20090192351 Nishino Jul 2009 A1
20090192368 Say et al. Jul 2009 A1
20090192369 Say et al. Jul 2009 A1
20090192370 Say et al. Jul 2009 A1
20090192371 Say et al. Jul 2009 A1
20090192372 Say et al. Jul 2009 A1
20090192373 Say et al. Jul 2009 A1
20090192374 Say et al. Jul 2009 A1
20090192375 Say et al. Jul 2009 A1
20090192376 Say et al. Jul 2009 A1
20090192377 Say et al. Jul 2009 A1
20090192378 Say et al. Jul 2009 A1
20090192379 Say et al. Jul 2009 A1
20090194747 Zou et al. Aug 2009 A1
20090197068 Yamaguchi et al. Aug 2009 A1
20090198115 Say et al. Aug 2009 A1
20090198116 Say et al. Aug 2009 A1
20090198175 Say et al. Aug 2009 A1
20090203964 Shimizu et al. Aug 2009 A1
20090203971 Sciarappa Aug 2009 A1
20090203972 Heneghan Aug 2009 A1
20090203978 Say et al. Aug 2009 A1
20090204265 Hackett Aug 2009 A1
20090210164 Say et al. Aug 2009 A1
20090216101 Say et al. Aug 2009 A1
20090216102 Say et al. Aug 2009 A1
20090227204 Robertson et al. Sep 2009 A1
20090227876 Tran Sep 2009 A1
20090227940 Say et al. Sep 2009 A1
20090227941 Say et al. Sep 2009 A1
20090227988 Wood et al. Sep 2009 A1
20090228214 Say et al. Sep 2009 A1
20090231125 Baldus Sep 2009 A1
20090234200 Husheer Sep 2009 A1
20090243833 Huang Oct 2009 A1
20090253960 Takenaka et al. Oct 2009 A1
20090256702 Robertson Oct 2009 A1
20090260212 Schmett et al. Oct 2009 A1
20090264714 Chou Oct 2009 A1
20090264964 Abrahamson Oct 2009 A1
20090265186 Tarassenko et al. Oct 2009 A1
20090273467 Elixmann Nov 2009 A1
20090281539 Selig Nov 2009 A1
20090287109 Ferren et al. Nov 2009 A1
20090295548 Ronkka Dec 2009 A1
20090296677 Mahany Dec 2009 A1
20090303920 Mahany Dec 2009 A1
20090306633 Trovato et al. Dec 2009 A1
20090312619 Say et al. Dec 2009 A1
20090318303 Delamarche et al. Dec 2009 A1
20090318761 Rabinovitz Dec 2009 A1
20090318779 Tran Dec 2009 A1
20090318783 Rohde Dec 2009 A1
20090318793 Datta Dec 2009 A1
20100001841 Cardullo Jan 2010 A1
20100010330 Rankers Jan 2010 A1
20100033324 Shimizu et al. Feb 2010 A1
20100036269 Ferren et al. Feb 2010 A1
20100049004 Edman et al. Feb 2010 A1
20100049006 Magar Feb 2010 A1
20100049012 Dijksman et al. Feb 2010 A1
20100049069 Tarassenko et al. Feb 2010 A1
20100056878 Partin Mar 2010 A1
20100056891 Say et al. Mar 2010 A1
20100056939 Tarassenko et al. Mar 2010 A1
20100057041 Hayter Mar 2010 A1
20100062709 Kato Mar 2010 A1
20100063438 Bengtsson Mar 2010 A1
20100063841 D'Ambrosia et al. Mar 2010 A1
20100069002 Rong Mar 2010 A1
20100069717 Hafezi et al. Mar 2010 A1
20100099967 Say et al. Apr 2010 A1
20100099968 Say et al. Apr 2010 A1
20100099969 Say et al. Apr 2010 A1
20100100077 Rush Apr 2010 A1
20100100078 Say et al. Apr 2010 A1
20100106001 Say et al. Apr 2010 A1
20100118853 Godfrey May 2010 A1
20100139672 Kroll et al. Jun 2010 A1
20100168659 Say et al. Jul 2010 A1
20100179398 Say et al. Jul 2010 A1
20100185055 Robertson Jul 2010 A1
20100191073 Tarassenko et al. Jul 2010 A1
20100210299 Gorbachov Aug 2010 A1
20100222652 Cho Sep 2010 A1
20100228113 Solosko Sep 2010 A1
20100233026 Ismagliov et al. Sep 2010 A1
20100234706 Gilland Sep 2010 A1
20100234715 Shin Sep 2010 A1
20100234914 Shen Sep 2010 A1
20100245091 Singh Sep 2010 A1
20100249541 Geva et al. Sep 2010 A1
20100249881 Corndorf Sep 2010 A1
20100256461 Mohamedali Oct 2010 A1
20100259543 Tarassenko et al. Oct 2010 A1
20100268048 Say et al. Oct 2010 A1
20100268049 Say et al. Oct 2010 A1
20100268050 Say et al. Oct 2010 A1
20100274111 Say et al. Oct 2010 A1
20100280345 Say et al. Nov 2010 A1
20100280346 Say et al. Nov 2010 A1
20100295694 Kauffman et al. Nov 2010 A1
20100297640 Kumar et al. Nov 2010 A1
20100298650 Moon et al. Nov 2010 A1
20100298668 Hafezi et al. Nov 2010 A1
20100298730 Tarassenko et al. Nov 2010 A1
20100312188 Robertson et al. Dec 2010 A1
20100312580 Tarassenko et al. Dec 2010 A1
20110009715 O'Reilly et al. Jan 2011 A1
20110054265 Hafezi et al. Mar 2011 A1
20110065983 Hafezi et al. Mar 2011 A1
20110077660 Janik et al. Mar 2011 A1
20110105864 Robertson et al. May 2011 A1
20110124983 Kroll et al. May 2011 A1
20110134906 Garudadri et al. Jun 2011 A1
20110160549 Saroka et al. Jun 2011 A1
20110224912 Bhavaraju et al. Sep 2011 A1
20110230732 Edman et al. Sep 2011 A1
20110270135 Dooley et al. Nov 2011 A1
20120004520 Whitworth et al. Jan 2012 A1
20120011699 Hafezi et al. Jan 2012 A1
20120016231 Westmoreland Jan 2012 A1
20120032816 Cho et al. Feb 2012 A1
20120059257 Duck et al. Mar 2012 A1
20120062371 Radivojevic et al. Mar 2012 A1
20120071743 Todorov et al. Mar 2012 A1
20120109112 Strand et al. May 2012 A1
20120179004 Roesicke et al. Jul 2012 A1
20120245043 England Sep 2012 A1
20120276451 Lestriez et al. Nov 2012 A1
20120299723 Hafezi et al. Nov 2012 A1
20130030366 Robertson et al. Jan 2013 A1
20130129869 Hafezi et al. May 2013 A1
20130129872 Kruger May 2013 A1
20130131283 Wang et al. May 2013 A1
20130144132 Hafezi et al. Jun 2013 A1
20130171596 French Jul 2013 A1
20130172690 Arne et al. Jul 2013 A1
20130185228 Dresner Jul 2013 A1
20130196012 Dill Aug 2013 A1
20130199662 Gebbink Aug 2013 A1
20130209877 Kren et al. Aug 2013 A1
20130223028 Arne et al. Aug 2013 A1
20130275296 Tietzen et al. Oct 2013 A1
20140066734 Zdeblick Mar 2014 A1
20140179221 Whitworth et al. Jun 2014 A1
20140180202 Zdeblick et al. Jun 2014 A1
20140280125 Bhardwaj et al. Sep 2014 A1
20140308930 Tran Oct 2014 A1
20140349256 Connor Nov 2014 A1
20140374276 Guthrie et al. Dec 2014 A1
20150017486 Lai Jan 2015 A1
20150059922 Thompson et al. Mar 2015 A1
20150080677 Thompson et al. Mar 2015 A1
20150080679 Frank et al. Mar 2015 A1
20150080680 Zdeblick et al. Mar 2015 A1
20150080681 Hafezi et al. Mar 2015 A1
20150112243 Hafezi et al. Apr 2015 A1
20150127737 Thompson et al. May 2015 A1
20150127738 Thompson et al. May 2015 A1
20150149375 Thompson et al. May 2015 A1
20150150480 Zdeblick et al. Jun 2015 A1
20150164746 Costello et al. Jun 2015 A1
20150173646 Berkman et al. Jun 2015 A1
20150223751 Zdeblick et al. Aug 2015 A1
20150230729 Zdeblick et al. Aug 2015 A1
20150248833 Arne et al. Sep 2015 A1
20150352343 Hafezi et al. Dec 2015 A1
20150361234 Hafezi et al. Dec 2015 A1
20160033667 Schmidt et al. Feb 2016 A1
20160174900 Zdeblick et al. Jun 2016 A1
20160345906 Johnson et al. Dec 2016 A1
20160380708 Dua et al. Dec 2016 A1
20170000179 Cheng et al. Jan 2017 A1
20170014046 Hafezi et al. Jan 2017 A1
20170020182 Schmidt et al. Jan 2017 A1
20170216569 Hafezi et al. Aug 2017 A1
20170265813 Zdeblick et al. Sep 2017 A1
20170274194 Robertson et al. Sep 2017 A1
20170296799 Hafezi et al. Oct 2017 A1
20180026680 Shirvani et al. Jan 2018 A1
20180110441 Frank et al. Apr 2018 A1
20180184698 Arne et al. Jul 2018 A1
20180214048 Zdeblick et al. Aug 2018 A1
20180229996 Thompson Aug 2018 A1
20190158151 Shirvani et al. May 2019 A1
Foreign Referenced Citations (167)
Number Date Country
1588649 Mar 2005 CN
1650844 Aug 2005 CN
101795202 Aug 2010 CN
10313005 Oct 2004 DE
0344939 Dec 1989 EP
0526166 Feb 1993 EP
0981152 Feb 2000 EP
1246356 Oct 2002 EP
1534054 May 2005 EP
1702553 Sep 2006 EP
1244308 Dec 2007 EP
2143369 Jan 2010 EP
827762 Feb 1960 GB
61072712 Apr 1986 JP
H01285247 Nov 1989 JP
05-228128 Sep 1993 JP
H11195415 Jul 1999 JP
2000-506410 May 2000 JP
2002263185 Sep 2002 JP
2002282219 Oct 2002 JP
2003050867 Feb 2003 JP
2004-313242 Nov 2004 JP
2005-073886 Mar 2005 JP
2005-087552 Apr 2005 JP
2005-304880 Apr 2005 JP
2005102959 Apr 2005 JP
2005124708 May 2005 JP
2005514966 May 2005 JP
2005343515 Dec 2005 JP
20055332328 Dec 2005 JP
2006006377 Jan 2006 JP
2006509574 Mar 2006 JP
2007200739 Aug 2007 JP
2007-313340 Dec 2007 JP
2009514870 Apr 2009 JP
2009528909 Aug 2009 JP
2006077523 Jul 2006 KR
200406192 May 2004 TW
200916136 Apr 2009 TW
WO1988002237 Apr 1988 WO
WO1992021307 Dec 1992 WO
WO1993008734 May 1993 WO
WO1993019667 Oct 1993 WO
WO1994001165 Jan 1994 WO
WO1997039963 Oct 1997 WO
WO1998043537 Oct 1998 WO
WO1999037290 Jul 1999 WO
WO1999059465 Nov 1999 WO
WO2000032474 Jun 2000 WO
WO2000033246 Jun 2000 WO
WO2001047466 Jul 2001 WO
WO2001058236 Aug 2001 WO
WO2001074011 Oct 2001 WO
WO2001080731 Nov 2001 WO
WO2002000920 Jan 2002 WO
WO2002045489 Jun 2002 WO
WO2002058330 Jul 2002 WO
WO2002062276 Aug 2002 WO
WO2002087681 Nov 2002 WO
WO2002095351 Nov 2002 WO
WO2003005877 Jan 2003 WO
WO2003050643 Jun 2003 WO
WO2003068061 Aug 2003 WO
WO2004014225 Feb 2004 WO
WO2004019172 Mar 2004 WO
WO2004039256 May 2004 WO
WO2004066833 Aug 2004 WO
WO2004066834 Aug 2004 WO
WO2004066903 Aug 2004 WO
WO2004068881 Aug 2004 WO
WO2004075032 Sep 2004 WO
WO2004109316 Dec 2004 WO
WO2005011237 Feb 2005 WO
WO2005020023 Mar 2005 WO
WO2005024687 Mar 2005 WO
WO2005041438 May 2005 WO
WO2005047837 May 2005 WO
WO2005051166 Jun 2005 WO
WO2005053517 Jun 2005 WO
WO2005083621 Sep 2005 WO
WO2005110238 Nov 2005 WO
WO2005123569 Dec 2005 WO
WO2006021932 Mar 2006 WO
WO2006027586 Mar 2006 WO
WO2006028347 Mar 2006 WO
WO2006055892 May 2006 WO
WO2006055956 May 2006 WO
WO2006075016 Jul 2006 WO
WO2006100620 Sep 2006 WO
WO2006116718 Nov 2006 WO
WO2006127355 Nov 2006 WO
WO2007001724 Jan 2007 WO
WO2007001742 Jan 2007 WO
WO2007013952 Feb 2007 WO
WO2007014084 Feb 2007 WO
WO2007014527 Feb 2007 WO
WO2007021496 Feb 2007 WO
WO2007027660 Mar 2007 WO
WO2007028035 Mar 2007 WO
WO2007036687 Apr 2007 WO
WO2007036741 Apr 2007 WO
WO2007036746 Apr 2007 WO
WO2007040878 Apr 2007 WO
WO2007067054 Jun 2007 WO
WO2007071180 Jun 2007 WO
WO2007096810 Aug 2007 WO
WO2007101141 Sep 2007 WO
WO2007115087 Oct 2007 WO
WO2007120946 Oct 2007 WO
WO2007127316 Nov 2007 WO
WO2007127879 Nov 2007 WO
WO2007128165 Nov 2007 WO
WO2007130491 Nov 2007 WO
WO2007143535 Dec 2007 WO
WO2007149546 Dec 2007 WO
WO2006104843 Jan 2008 WO
WO2008008281 Jan 2008 WO
WO2008012700 Jan 2008 WO
WO2008030482 Mar 2008 WO
WO2008052136 May 2008 WO
WO2008063626 May 2008 WO
WO2008066617 Jun 2008 WO
WO2008076464 Jun 2008 WO
WO2008089232 Jul 2008 WO
WO2008091683 Jul 2008 WO
WO2008095183 Aug 2008 WO
WO2008097652 Aug 2008 WO
WO2008101107 Aug 2008 WO
WO2008112577 Sep 2008 WO
WO2008112578 Sep 2008 WO
WO2008120156 Oct 2008 WO
WO2008133394 Nov 2008 WO
WO2008134185 Nov 2008 WO
WO2008150633 Dec 2008 WO
WO2009000447 Dec 2008 WO
WO2009001108 Dec 2008 WO
WO2009006615 Jan 2009 WO
WO2009029453 Mar 2009 WO
WO2009031149 Mar 2009 WO
WO2009036334 Mar 2009 WO
WO2009051829 Apr 2009 WO
WO2009051830 Apr 2009 WO
WO2009063377 May 2009 WO
WO2009081348 Jul 2009 WO
WO2009111664 Sep 2009 WO
WO2009146082 Dec 2009 WO
WO2001000085 Jan 2010 WO
WO2010009100 Jan 2010 WO
WO2010011833 Jan 2010 WO
WO2010019778 Feb 2010 WO
WO2010057049 May 2010 WO
WO2010080765 Jul 2010 WO
WO2010080843 Jul 2010 WO
WO2010107563 Sep 2010 WO
WO2010129288 Nov 2010 WO
WO2010132331 Nov 2010 WO
WO2010135516 Nov 2010 WO
WO2011068963 Jun 2011 WO
WO2011133799 Oct 2011 WO
WO2011159336 Dec 2011 WO
WO2011159337 Dec 2011 WO
WO2011159338 Dec 2011 WO
WO2011159339 Dec 2011 WO
WO2012112561 Aug 2012 WO
WO2015112603 Jul 2015 WO
WO2015112604 Jul 2015 WO
WO2015119911 Aug 2015 WO
Non-Patent Literature Citations (86)
Entry
Au-Yeung, K., et al., “A Networked System for Self-Management of Drug Therapy and Wellness”, Wireless Health '10, Oct. 5-7, 2010, San Diego, 9 pages.
AADE, “AADE 37th Annual Meeting San Antonio Aug. 4-7, 2010” American Association of Diabetes Educators (2010); http://www.diabeteseducator.org/annualmeeting/2010/index.html; 2 pp.
Arshak et al., A Review and Adaptation of Methods of Object Tracking to Telemetry Capsules IC-Med (2007) vol. 1, No. 1, Issue 1, 12pp.
“ASGE Technology Status Evaluation Report: wireless capsule endoscopy” American Soc. For Gastrointestinal Endoscopy (2006) vol. 63, No. 4; 7 pp.
Aydin et al., “Design and implementation considerations for an advanced wireless interface in miniaturized integrated sensor Microsystems” Sch. of Eng. & Electron., Edinburgh Univ., UK; (2003); abstract.
Barrie, Heidelberg pH capsule gastric analysis. Texbook of Natural Medicine, (1992), Pizzorno, Murray & Barrie.
Bohidar et al., “Dielectric Behavior of Gelatin Solutions and Gels” Colloid Polym Sci (1998) 276:81-86.
Brock, “Smart Medicine: The Application of Auto-ID Technology to Healthcare” Auto-ID Labs (2002) http://www.autoidlabs.org/uploads/media/MIT-AUTOID-WH-010.pdf.
Carlson et al., “Evaluation of a non-invasive respiratory monitoring system for sleeping subjects” Physiological Measurement (1999) 20(1): 53.
Coury, L. “Conductance Measurement Part 1: Theory”; Current Separations, 18:3 (1999) p. 91-96.
Delvaux et al., “Capsule endoscopy: Technique and indications” Clinical Gastoenterology (2008) vol. 22, Issue 5, pp. 813-837.
Dhar et al., “Electroless nickel plated contacts on porous silicon” Appl. Phys. Lett. 68 (10) pp. 1392-1393 (1996).
Eldek A., “Design of double dipole antenna with enhanced usable bandwidth for wideband phased array applications” Progress in Electromagnetics Research PIER 59, 1-15 (2006).
Fawaz et al., “Enhanced Telemetry System using CP-QPSK Band—Pass Modulation Technique Suitable for Smart Pill Medical Application” IFIP IEEE Dubai Conference (2008); http://www.asic.fh-offenburg.de/downloads/ePille/IFIP_IEEE_Dubai_Conference.pdf.
Ferguson et al., “Dialectric Constant Studies III Aqueous Gelatin Solutions” J. Chem. Phys. 2, 94 (1934) p. 94-98.
Furse C. M., “Dipole Antennas” J. Webster (ed). Wiley Encyclopedia of Electrical and Electronics Engineering (1999) p. 575-581.
Gaglani S. “Put Your Phone, or Skin, on Vibrate” MedGadget (2012) http://medgadget.com/2012/03/put-your-phone-or-skin-on-vibrate.html 8pp.
Gilson, D.R. “Molecular dynamics simulation of dipole interactions”, Department of Physics, Hull University, Dec. (2002), p. 1-43.
Given Imaging, “Agile Patency Brochure” (2006) http://www.inclino.no/documents/AgilePatencyBrochure_Global_GMB-0118-01.pdf; 4pp.
Gonzalez-Guillaumin et al., “Ingestible capsule for impedance and pH monitoring in the esophagus” IEEE Trans Biomed Eng. (2007) 54(12): 2231-6; abstract.
Greene, “Edible RFID microchip monitor can tell if you take your medicine” Bloomberg Businessweek (2010) 2 pp.; http://www.businessweek.com/idg/2010-03-31/edible-rfid-microchip-monitor-can-tell-if-you-take-your-medicine.html.
Heydari et al., “Analysis of the PLL jitter due to power/ground and substrate noise”; IEEE Transactions on Circuits and Systems (2004) 51(12): 2404-16.
Hoeksma, J. “New ‘smart pill’ to track adherence” E-Health-Insider (2010) http://www.e-health-insider.com/news/5910/new_‘smart_pill’_monitors_medicines.
Hoover et al., “Rx for health: Engineers design pill that signals it has been swallowed” University of Florida News (2010) 2pp.; http://news.ufl.edu/2010/03/31/antenna-pill-2/.
Intromedic, MicroCam Innovative Capsule Endoscope Pamphlet. (2006) 8 pp (http://www.intromedic.com/en/product/productinfo.asp).
ISFET—Ion Sensitive Field-Effect Transistor; MICROSENS S.A. pdf document. First cited by Examiner in Office Action dated Jun. 13, (2011) for U.S. Appl. No. 12/238,345; 4pp.
Jung, S. “Dissolvable ‘Transient Electronics’ Will Be Good for Your Body and the Environment” MedGadget; Oct. 1, (2012); Onlne website: http://medgadget.com/2012/10/dissolvable-transient-electronics-will-be-good-for-your-body-and-the-environment.html; downloaded Oct. 24, 2012; 4 pp.
Juvenile Diabetes Research Foundation International (JDRF), “Artificial Pancreas Project” (2010); http://www.artificialpancreasproject.com/; 3 pp.
Kamada K., “Electrophoretic deposition assisted by soluble anode” Materials Letters 57 (2003) 2348-2351.
Kendle, Earl R. and Morris, Larry A., “Preliminary Studies in the Development of a Gastric Battery for Fish” (1964). Nebraska Game and Parks Commission White Papers, Conference Presentations, & Manuscripts. Paper 22. p. 1-6.
Kim et al., “A Semi-Interpenetrating Network System for a Polymer Membrane”; Eur. Polym. J. vol. 33 No. 7; pp. 1009-1014 (1997).
Li, P-Y, et al. “An electrochemical intraocular drug delivery device”, Sensors and Actuators A 143 (2008) p. 41-48.
Lifescan, “OneTouch UltraLink™” http://www.lifescan.com/products/meters/ultralink (2010) 2 pp.
Mackay et al., “Radio Telemetering from within the Body” Inside Information is Revealed by Tiny Transmitters that can be Swallowed or Implanted in Man or Animal Science (1991) 1196-1202; 134; American Association for the Advancement of Science, Washington D.C.
Mackay et al., “Endoradiosonde” Nature, (1957) 1239-1240, 179 Nature Publishing Group.
McKenzie et al., “Validation of a new telemetric core temperature monitor” J. Therm. Biol. (2004) 29(7-8):605-11.
Medtronic, “CareLink Therapy Management Software for Diabetes” (2010); https://carelink.minimed.com/patient/entry.jsp?bhcp=1; 1 pp.
Medtronic, “Carelink™ USB” (2008) http://www.medtronicdiabetes.com/pdf/carelink_usb_factsheet.pdf 2pp.
Medtronic “The New MiniMed Paradigm® REAL-Time Revel™ System” (2010) http://www.medtronicdiabetes.com/products/index.html; 2 pp.
Medtronic, “MINI MED Paradigm® Revel™ Insulin Pump” (2010) http://www.medtronicdiabetes.com/products/insulinpumps/index.html; 2pp.
Medtronic, Mini Med Paradigm™ Veo™ System: Factsheet (2010). http://www.medtronic-diabetes.com.au/downloads/Paradigm%20Veo%20Factsheet.pdf ; 4 pp.
Melanson, “Walkers swallow RFID pills for science” Engadget (2008); http://www.engadget.com/2008/07/29/walkers-swallow-rfid-pills-for-science/.
Minimitter Co. Inc. “Actiheart” Traditional 510(k) Summary. Sep. 27, (2005).
Minimitter Co. Inc. Noninvasive technology to help your studies succeed. Mini Mitter.com Mar. 31, (2009).
Mini Mitter Co, Inc. 510(k) Premarket Notification Mini-Logger for Diagnostic Spirometer. Sep. 21, (1999).
Mini Mitter Co, Inc. 510(k) Premarket Notification for VitalSense. Apr. 22, (2004).
Minimitter Co. Inc. VitalSense Integrated Physiological Monitoring System. Product Description. (2005).
Minimitter Co. Inc. VitalSense Wireless Vital Signs Monitoring. Temperatures.com Mar. 31, (2009).
Mojaverian et al., “Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition” Gastroenterology (1985) 89:(2): 392-7.
O'Brien et al., “The Production and Characterization of Chemically Reactive Porous Coatings of Zirconium Via Unbalanced Magnetron Sputtering” Surface and Coatings Technology (1996) 86-87; 200-206.
Park, “Medtronic to Buy MiniMed for $3.7 Billion” (2001) HomeCare; http://homecaremag.com/mag/medical_medtronic_buy_minimed/; 2 pp.
Radio Antennae, http://www.erikdeman.de/html/sail018h.htm; (2008) 5 pages.
“RFID “pill” monitors marchers” RFID News (2008) http://www.rfidnews.org/2008/07/23/rfid-pill-monitors-marchers/.
Rolison et al., “Electrically conductive oxide aerogels: new materials in electrochemistry” J. Mater. Chem. (2001) 1, 963-980.
Roulstone, et al., “Studies on Polymer Latex Films: I. A study of latex film morphology” Polymer International 24 (1991) pp. 87-94.
Sanduleanu et al., “Octave tunable, highly linear, RC-ring oscillator with differential fine-coarse tuning, quadrature outputs and amplitude control for fiber optic transceivers” (2002) IEEE MTT-S International Microwave Symposium Digest 545-8.
Santini, J.T. et al, “Microchips as controlled drug delivery-devices”, Agnew. Chem. Int. Ed. (2000), vol. 39, p. 2396-2407.
“SensiVida minimally invasive clinical systems” Investor Presentation Oct. (2009) 28pp; http://www.sensividamedtech.com/SensiVidaGeneralOctober09.pdf.
Shawgo, R.S. et al. “BioMEMS from drug delivery”, Current Opinion in Solid State and Material Science 6 (2002), p. 329-334.
Shin et al., “A Simple Route to Metal Nanodots and Nanoporous Metal Films”; Nano Letters, vol. 2, No. 9 (2002) pp. 933-936.
Shrivas et al., “A New Platform for Bioelectronics-Electronic Pill”, Cummins College, (2010).; http://www.cumminscollege.org/downloads/electronics_and_telecommunication/Newsletters/Current%20Newsletters.pdf; First cited in third party client search conducted by Patent Eagle Search May 18, 2010 (2010).
“Smartlife awarded patent for knitted transducer” Innovation in Textiles News: http://www.innovationintextiles.com/articles/208.php; 2pp. (2009).
“The SmartPill Wireless Motility Capsule” SmartPill, The Measure of GI Health; (2010) http://www.smartpillcorp.com/index.cfm?pagepath=Products/The_SmartPill_Capsule&id=17814.
Solanas et al., “RFID Technology for the Health Care Sector” Recent Patents on Electrical Engineering (2008) 1, 22-31.
Soper, S.A. et al. “Bio-Mems Technologies and Applications”, Chapter 12, “MEMS for Drug Delivery”, p. 325-346 (2007).
Swedberg, “University Team Sees Ingestible RFID Tag as a Boon to Clinical Trials” RFID Journal Apr. 27, (2010); http://www.rfidjournal.com/article/view/7560/1 3pp.
Tajalli et al., “Improving the power-delay performance in subthreshold source-coupled logic circuits” Integrated Circuit and System Design. Power and Timing Modeling, Optimization and Simulation, Springer Berlin Heidelberg (2008) 21-30.
Tatbul et al., “Confidence-based data management for personal area sensor networks” ACM International Conference Proceeding Series (2004) 72.
Tierney, M.J. et al “Electroreleasing Composite Membranes for Delivery of Insulin and other Biomacromolecules”, J. Electrochem. Soc., vol. 137, No. 6, Jun. (1990), p. 2005-2006.
Trutag Technologies, Inc., Spectral Microtags for Authentication and Anti-Counterfeiting; “Product Authentication and Brand Protection Solutions”; http://www.trutags.com/; downloaded Feb. 12, 2013; 1 pp.
Walkey, “MOSFET Structure and Processing”; 97.398* Physical Electronics Lecture 20; 24 pp.
Watson, et al., “Determination of the relationship between the pH and conductivity of gastric juice” Physiol Meas. 17 (1996) pp. 21-27.
Whipple, Fred L.; “Endoradiosonde,” Nature, Jun. 1957, 1239-1240.
Winter, J. et al. “The material properties of gelatin gels”; USA Ballistic Research Laboratories, Mar. (1975), p. 1-157.
Wongmanerod et al., “Determination of pore size distribution and surface area of thin porous silicon layers by spectroscopic ellipsometry” Applied Surface Science 172 (2001) 117-125.
Xiaoming et al., “A telemedicine system for wireless home healthcare based on bluetooth and the internet” Telemedicine Journal and e-health (2004) 10(S2): S110-6.
Yang et al., “Fast-switching frequency synthesizer with a discriminator-aided phase detector” IEEE Journal of Solid-State Circuits (2000) 35(10): 1445-52.
Yao et al., “Low Power Digital Communication in Implantable Devices Using Volume Conduction of Biological Tissues” Proceedings of the 28th IEEE, EMBS Annual International Conference, Aug. 30-Sep. 3, (2006).
Zimmerman, “Personal Area Networks: Near-field intrabody communication” IBM Systems Journal (1996) 35 (3-4):609-17.
Description of ePatch Technology Platform for ECG and EMG, located it http://www.madebydelta.com/imported/images/DELTA_Web/documents/ME/ePatch_ECG_EMG.pdf, Dated Sep. 2, 2010.
Zworkin, “A Radio Pill” Nature, (1957) 898, 179 Nature Publishing Group.
Wang, X. et al “Resistance to Tracking and Erosion of Silicone Rubber Material under Various Types of Precipitation”, Jpn. J. Appl. Phys. vol. 38 (1999) pp. 5170-5175.
Philips Respironics Products, Noninvasive Technology to Help Your Studies Succeed. 510 (k) Permanent Notification for Vital Sense. Apr. 22, 2004; http/minimitter.com/products.cfm.
Target Innovations, Tablet Metal Detector, https ://web. arch ive.org/web/20 130215063351/http://www. metaldetectorindia.com/tablet -metal-detector. html, Feb. 15, 2013.
TargetPharmaceutical Metal Detector, Feb. 15, 2013 downloaded from Target Innovations, Tablet Metal Detector, Feb. 15, 2013.
Youtube video Pharmaceutical Metal Detector/Tablet Metal Detector/ Capsule Metal Detector/ Dry Fruits; https://www.youtube.com/watch?v=I0126txam_s, May 12, 2012.
Related Publications (1)
Number Date Country
20150080678 A1 Mar 2015 US
Continuations (1)
Number Date Country
Parent 13180525 Jul 2011 US
Child 14308548 US